

NATIONAL INSTITUTE OF MENTAL HEALTH AND NEURO SCIENCES

(An Institute of National Importance, under Ministry of Health and Family Welfare, Govt. of India)

HOSUR ROAD, BENGALURU - 560 029

राष्ट्रीय मानसिका स्वास्थ्य एवं तंत्रिका विझान संस्थान (राष्ट्रीय प्रमुख्याथा संस्थ) बेंगलुरू - 560 029 ರಾಷ್ಟ್ರೀಯ ಮಾನಸಿಕ ಆರೋಗ್ಯ ಮತ್ತು ನರವಿಜ್ಞಾನ (ರಾಷ್ಟ್ರೀಯ ಪ್ರಾಮುಖ್ಯತೆ ಸಂಸ್ಥೆ), ಬೆಂಗಳೂರು -560 029

website: www.nimhans.ac.in

email.: aaoh@nimhans.ac.in / aaohospital@gmail.com

No. NIMH/PU-I(D)/TENDER/RC(23-24)/01/2022-23

DATED:09.01.2023

E-procurement Tender No. NIMHANS/2022-23/IND866

TENDER NOTIFICATION

(Through Karnataka e-procurement portal only)

The Director, NIMHANS invites tender from eligible tenderers through the Karnataka Government E-procurement portal for supply of various kinds of Drugs, Chemicals and Miscellaneous items required in the NIMHANS Hospital for a period of 12 months from the date of issue of Rate Contract. The validity of Rate Contract from 01.04.2023 to 31.03.2024.

- 1. Tenderer can download the tender form and other details from the NIMHANS/Karnataka e-procurement website. The filled tender forms should be submitted on or before 09.02.2023 through e-procurement portal. The tender will be summarily rejected whenever copy of EMD receipt is not enclosed.
 - "A primary manufacturer" is defined as a person/ company having an own manufacturing unit that performs all the manufacturing and processing operations needed to produce drugs in their appropriate dosage forms, including processing, blending, formulating, filling, packing, labelling & quality testing with a valid license under the Drugs & Cosmetics Act. 1940 & Rules, but not include loan licenses.
 - "Loan License Manufacturer" (Manufacturers engaged in manufacturing under, 'Loan License' obtained under the Drugs & Cosmetics Act, 1940 & Rules) are not considered as Primary Manufacturers and hence they are not eligible.
- 2. Tender not submitted in the prescribed form within due date will be rejected.
- 3. All manufacturers should supply the selected/awarded drugs/ items directly to the NIMHANS, Bengaluru however, if it is not possible to supply directly, the tenderers can choose only one prompt supplier to supply the items with all aspects, failing which tender will be cancelled.
- 4. Tender of only those tenderers who fulfil the terms and conditions of this tender will be considered for evaluation and will be allowed to participate in the process. No distributors/stockists will be allowed to participate in the processing of tender.
- 5. The tenders will undergo evaluation at every stage of processing and any tender found at any stage not being in conformity with the stipulated tender conditions including specification/ found to have furnished defective documents/ incomplete documents/ samples of the items found not in conformity with the specifications or found defective either physically or analytically will be rejected.
- 6. Those who intend to submit tender documents can attend the tentative pre-bid meeting scheduled to be held on 27.01.2023 at 11.00PM onwards venue at Ashwini Hall, Ashwini Block. NIMHANS.
 - Further, all the tenderers/bidders are advised to kindly submit their representation for discussion in Pre-Bid meeting through email: aaohospital@gmail.com /

<u>aaoh@nimhans.ac.in</u> up to <u>20.01.2023@12.00PM</u> clarifications received after the pre-bid due date will not be entertained.

7. Critical date sheet:

| a. | Commencement of Tender forms downloaded from NIMHANS | 11.01.2023 at |
|----|---|---------------|
| | website | 04:00PM |
| b. | Pre-bid meeting | 27.01.2023 at |
| | Venue : Ashwini Hall, Ashwini Block, NIMHANS | 11:00AM |
| C. | Last date of submission of filled Tender forms along with samples | 09.02.2023 at |
| | | 11:00AM |
| d. | Opening of Technical Bid at Ashwini Hall, NIMHANS | 10.02.2023, |
| | | AT 11:00AM |

8. Opening of Financial Bid:

Financial Bids of only those technically successful responsive bids will be opened on a date notified/informed to the responsive Bidders and announced in NIMHANS web portal

• Corrigendum, if any will be published only in NIMHANS portal http://www.nimhans.ac.in

DIRECTOR & Tendering Authority

TERMS AND CONDITIONS OF THE TENDER

- Separate quotation needs to be submitted for Drugs, Chemicals & Surgicals (Listed in Annexure - C)
 - 1.1. The tender shall be submitted only if the bidder is agreeable to all the terms and conditions of this tender, which includes the description and Specifications of the items mentioned therein.
 - 1.2. The Bidder shall submit the tenders in two bid system in Karnataka e-procurement portal.
 - 1.3. The Drugs, Chemicals & Surgicals items required are listed category-wise with specific code number in Annexure
 - 1.4. The bidder shall fill in the Tender offer form (provided in Annexure A) and submit.
 - 1.5. Irrespective of the terms and conditions the bidder may have specified, only the terms and conditions specified in this tender shall be binding on the bidder and the tendering authority.

2. EARNEST MONEY DEPOSIT:

- 2.1. The Earnest Money Deposit for the purpose of this tender is ₹1,00,000/- for the Drugs, Chemicals & Surgicals, EMD may be collected through e-procurement portal. The printed receipt of EMD should be uploaded in technical bid. Earnest Money Deposit in the form of Cheque/cash/postal order will not be accepted.
- 2.2. However, those firms who are having valid MSME / SSI / Udyog Aadhar certificate for manufacturing of Drugs, appropriate Govt. of India guidelines shall be followed.
- 2.3. Deposit in any other form, which may have been made earlier, or any payment pending with the purchaser will not be adjusted towards this Earnest Money Deposit
- 2.4. The EMD of unsuccessful Bidder will be returned in due course as per the e-portal policy.
- 2.5. No interest will be allowed on this deposit. Tenders not accompanied by the EMD in the form specified above will not be considered.
- 2.6. Failure to execute the agreement within the contract period on the part of the successful tenderer or withdrawal of his tender after the intimation of acceptance of tender has been sent to him/her or failure to comply with the contract owing to any other reasons will entail cancellation of his/her contract. The Earnest Money Deposit paid by the firm along with his/her tender will be forfeited and will also be liable for all damages sustained by the NIMHANS, Institute by reason of such breach and ultimately paid by the Institute for the items purchased at the current market rate. Such damages shall be assessed by the NIMHANS Institute whose decision is final and the amount so assessed is recoverable. In the event of such amounts being insufficient, the balance may be recovered personally from the bidder from his/her properties.

3. SECURITY DEPOSIT:

- 3.1. The bidder whose offer is accepted as L-I, L-II and L-III as preferred tenders, on being informed, should execute a Contract Agreement on Karnataka Government stamp paper in duplicate to the value of ₹200/- (Rupees Two hundred only) cost to be borne by the bidder as provided by Article 5 pf the Schedule of Karnataka Stamp Act. A copy of the contract agreement will be given to the Bidder. The specimen form of agreement will be available in NIMHANS.
- 3.2. The successful bidder whose offer is accepted shall be required to pay a Security Deposit as detailed below / 3% of the total value of supply per year calculated whichever is higher.

- 3.3. The agreement along with the specified "Security Deposit" should be submitted within 10 days from the date of receipt of the intimation of the Acceptance of offer.
- 3.4. Agreement not accompanied by the security deposit or any partial agreement, deleting certain items will not be accepted, and will be deemed as non-submission of agreement and violation of tender conditions and the Earnest Money Deposit of such bidders will be forfeited to NIMHANS without notice. Further, such bidder ceases to have any rights whatsoever in this regard with respect to the firms tender or the Rate Contract issued thereon. Firm is liable to be blacklisted too.
- 3.5. The original agreement shall be with the Tendering Authority. The bidder shall collect the signed copy of the agreement on his own. The purchaser shall not be responsible for the loss of the copy/ not collected.
- 3.6. The bidder is permitted to claim the Security Deposit on completion of the contract period including extended period if any, or after executing all the supplies satisfactorily, whichever is later. The refund of the Security Deposit shall be subject to satisfactory performance of the contract as per terms and conditions of contract. The Security Deposit not claimed within three years from the date of expiry of the contract shall be forfeited to NIMHANS without notice.

4. SUBMISSION OF TENDER DOCUMENT:

The Two Bid System i.e. "Technical Bid" and "Financial Bid" prepared by the tenderer shall comprise the following.

4.1. TECHNICAL BID

The bid contains only documents listed here under for mandatory qualification criteria:

- 4.1.1. The copy of online payment receipt towards EMD (Earnest Money Deposit) of ₹1,00,000/- (Rupees One lakh only) in respect of Drugs, Chemicals & Surgicals.
- 4.1.2. Self-attested Photocopy of GST Registration certificate, PAN card should be enclosed
- 4.1.3. Annual Turnover statement for three preceding years by the Commercial Tax Officer/ Chartered Accountant (i.e. for the years 2019-20,2020-21,2021-22). Minimum annual turnover should be minimum of ₹30,00,00,000/- (Rupees Thirty crores only) for all the participating tenderer/bidders.
- 4.1.4. Balance Sheet & Profit and Loss account for the years 2019-20,2020-21,2021-22 duly certified by the Chartered Accountant / Auditor shall be submitted. There should not be any negative balance.
- 4.1.5. The tenderer should furnish a copy of their latest manufacturing / Import License issued under Drugs and Cosmetics Act 1940 with authenticated list of drugs approved under the licence. If the firm is having multiple licence numbers for same products, the same shall be submitted.
- 4.1.6. Attested copy of Manufacturing License/ Individual drug License for both oral and parenteral issued under the Drugs & Cosmetics Act, 1940 and Rules duly renewed up to date along with the list of products permitted (Items to be quoted) wherever applicable shall be submitted, otherwise, it will be treated as "Non-Responsive". In case of Manufacturing Licence applied for renewal, it is insisted to produce the validity certificate form from the Licensing Authority in respect of their licence that it continues to be valid during the period of Tender process i.e. after submission for renewal, till the time the licence is actually been renewed.

- 4.1.7. Non-Conviction Certificate issued from the state Drug Controller and stating that no case pending against the organization/ firms under the Drugs & Cosmetics Act & Rules as well as Drugs (Price Control) Orders issued from time to time. It should be valid for preceding years
- 4.1.8. Detailed list of samples submitted should be enclosed. A copy of the same should be kept in the sealed container containing samples
- 4.1.9. Tenderer should have GMP/ Scheduled M compliance from CDSCO for Good Manufacturing Practice and requirements of premises, plant and equipment for pharmaceutical products should be enclosed and items made in India also are required to have GMP certification.
- 4.1.10. For imported items copy of the valid updated imported licence & registration certificate issued by Drug Controller General of India, as well as WHO-GMP certificate duly attested or notarized shall be submitted.
- 4.1.11. List of items quoted (the name and the code number of the items quoted alone should be furnished and the rates of those drugs should not be indicated in this list)
- 4.1.12. Declaration form from the bidder in the format enclosed as Annexure-B has to be furnished
- 4.1.13. Attested copy of valid SSI/MSME certificate issued by the Director of Industries and Commerce/ submitted copy of Udyog Aadhar certificate or equivalent, wherever applicable should be furnished.
- 4.1.14. ISO/BIS or equivalent certificate issued in respect of Gloves has to be furnished. Certificate to the effect of sterility verification from relevant statutory authority to be also submitted.
- 4.1.15. Tenderer should submit their FFS/BIS/ISI/ISO/WHO-GMP/CUNICEF certification, wherever applicable with notarisation.
- 4.1.16. The tenderer should also give a guarantee as follows, in case of biological and other products having a particular life-period to provide safe-guard against loss on account of deterioration within their stated period of potency.
 - "The tenderer/seller hereby declares that the drugs/goods sold to NIMHANS under this contract shall be of the best quality and shall be strictly in accordance with the specification and particulars mentioned in the description clauses hereof and the tenderer hereby guarantees that the said drugs/goods would continue to confirm to their description and quality for a period of one year from the date of delivery of the said drugs/goods or such portion thereof as may be discovered not to conform to the description and quality. Such rejection of the drugs/goods will be at the tenderer risk and all the provisions herein contained relating to rejection of drugs/goods etc., or such portion thereof if rejected by the NIMHANS shall be applicable. Otherwise, the tenderer shall pay to the NIMHANS such damages as may arise by reason of the breach of conditions herein contained. Nothing herein contained shall prejudice any other right of the Director, NIMHANS in that behalf under this contract or otherwise".
- 4.1.17. Certificate on self-attested non-judicial stamp paper of ₹10/- stating that there is no vigilance/ CBI case pending against the firm/supplier and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central government/ State Govt. departments/hospital/PSUs etc. tenderer should also provide information regarding blacklisting/debarring of the firm in last three years (2019-20, 2020-21 and 2021-22) by any government of Private Organisations/hospital. In case of any false information provided or concealed the information by any tenderer, the tenderer shall be debarred for

two years and EMD/ Bid Security/ security Deposit submitted by the firm shall be forfeited.

- 4.1.18. The firm should give an undertaking to the effect that they will be legally bound to supply the drugs/medicines, for which they have quoted the rates in the tender during the validity of the contract. In case, they fail to execute any purchase order placed to them within the time period mentioned in the agreement from the date of placement of purchase order, they will be liable for action against them as per tender terms.
- 4.1.19. Scanned copy of information as per the format enclosed should be submitted with the tender. Furnishing of false information will make the tenderer ineligible and the firm will stand blacklisted.
- 4.1.20. Only those companies regularly maintaining sufficient stock and ready/equipped to supply the quoted drugs within the lead time should participate.

Note:

- A. The Bidder quoting for items under import license shall produce the above listed documents pertaining to this parent manufacturers duly certified and formalized as per prevailing international norms or bilateral agreements between India and the exporting country.
- B. Tender documents shall not be transferable.
- C. However, in case of 'NEW DRUGS' as defined in Rule 122-E of the Drugs and Cosmetics Act, which may fall short of 3 years Market Standing, the bidder is allowed to claim it as a new drug as defined, in which case:
 - a. The bidder should furnish the Market Standing Certificate for the period over which he has manufactured and sold.
 - b. The bidder should furnish a synoptic statement of TEST REPORTS of all the batches from the first batch onwards he has manufactured and sold, duly signed by the bidder himself.

4.2. FINANCIAL BID:

The Financial Bid shall contain the (as specified in FORM-X) as following:

- 4.2.1. List of items and rates quoted in the prescribed form vide Annexure C
- 4.2.2. The rates like basic price, GST % with value and total price (include insurance and delivery charges) should be quoted. Revision of rates will not be allowed after opening the tender.
- 4.2.3. Rates should be quoted as per our specification. The contract rates should include charges for door delivery of the goods at the Pharmacy Main Stores, NIMHANS, Bengaluru-29
- 4.2.4. The rates quoted should be only in Indian Currency (INR), both in numbers & words. Quotes in any other currency/way shall be treated as non-responsive and rejected.
- 4.2.5. No tenderer/ bidder shall be allowed at any time and on any ground whatsoever, to claim for revision or modification of the rate quoted by them during the tender period.
- 4.2.6. The prices quoted by the tenderer shall not, if any case, exceed the controlled price, if any, fixed by the Govt. at the time of the supply of the item to the Institute. If the price quoted is found to be in excess of the controlled price permissible under the Drugs (Prices Control) Order, 2013, as amended from

- time to time, the bidder/tenderer should specifically mention this fact in his tender along with reasons for having quoted such high prices.
- 4.2.7. Tenders should be submitted only for the Drugs asked for, substitutes/ equivalents should not be offered. In case the drug asked for is not available and if rate for any of the item is not quoted, the column should be left blank.
- 4.2.8. Tenderers should be prepared to accept orders subject to the clause for forfeiture of EMD/Security Deposit in the event of default in supplies or failure to supply within the stipulated period.

4.3. QUOTATIONS:

- 4.3.1. Tender has been invited in the generic name of the Drugs, Chemicals and Miscellaneous items. The bidders should quote the rates for the same. The compositions and strength and specification of each product, should be as per details given in Annexure C, also the pharmacopoeia specification IP/BP/USP etc., wherever applicable should be clearly mentioned against each drug quoted as per provision of the Drug & Cosmetic Act. 1940 and Rules framed there under.
- 4.3.2. Tenderers must submit their quotations item wise i.e. per tablet, litre, capsule, etc. not as per packing size as has been asked appropriately in the tender.
- 4.3.3. Tender for the supply of drugs, chemicals etc. with conditions like "AT CURRENT MARKET RATE", "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., shall not be accepted. Handling, clearing, transport charges etc. will not be paid. The deliveries should be made as stipulated in the Purchase Order placed with successful bidders.
- 4.3.4. All corrections shall be duly attested with full signature.
- 4.3.5. The rates quoted should not be linked to the quantum of the order of destination.
- 4.3.6. Quotation should be entered in the portal.
- 4.3.7. The rates quoted when accepted shall be binding on the Bidder for the entire contract period.
- 4.3.8. No bidder shall be allowed at any time on any ground whatsoever to claim revision of or modification in the rates quoted by him. Clerical error, typographical error etc. committed by the bidders in the tender forms shall not be considered after opening of the tenders.
- 4.3.9. Only the primary manufacturer for manufacturing of that particular products should submit the quotation. Marketing products, 3rd party manufacturing drugs, loan licensing products shall not be accepted. In case such tenders are submitted, their quotations their bids will be summarily rejected without any notice by NIMHANS
- 4.3.10. For Multivitamin and B-Complex preparations in parenteral / liquid/ solid dosage forms should be quoted only as per the specified formula in the tender.

4.4. LATE TENDER:

There is NO PROVISION for late tender beyond stipulated date & time in the tender document. In case any tender received after the due date the same will be rejected by NIMHANS, Bengaluru without further notice. No paper tender submission is allowed.

4.5. LANGUAGE OF BID:

4.5.1. The bid submitted by the tenderer and all subsequent correspondence and documents relating to the tender exchanged between the tenderer and NIMHANS, shall be written in the **English language**. However, the language

of any printed literature furnished by the tenderer in connection with its tender may be written in any other language provided the same is accompanied by an English translation and, for purposes of interpretation of the tender, the English translation shall prevail.

4.6. ALTERATION AND WITHDRAWAL OF TENDER:

- 4.6.1. The tenderer, will not be allowed to make any alterations/ modifications to bids received after the prescribed time period.
- 4.6.2. No bid should be withdrawn after the deadline for submission of bid and before expiry of the bid validity period. If a bidder withdraws the bid during this period, it will result in forfeiture of the EMD furnished by the tenderer in its bid/ tender.

5. Mandatory Minimum Qualification Criteria:

- 5.1. Only **primary manufacturers are eligible** to participate this tender. Further the authorized suppliers/ distributors/ stockiest are not eligible for the same.
- 5.2. Manufacturing & Market Standing/ experience certificate of minimum "**Three years**" of the molecule quoted by them duly certified by the Central / State Drug Controller. The certificate should have been issued recently i.e. not more than six months from the date of the opening of the tender.
- 5.3. Valid WHO-GMP/ GMP certificate/ Schedule M certificate issued by Centre/ State Drugs Controller
- 5.4. In case of imported drugs (i.e. not manufactured in India), COPP (Certificate of Pharmaceutical Products)/ Import license and copy of import registration of that particular molecule quoted in the tender indicating the list of products should be submitted as per WHO norms and "3-years" Marketing experience certificate issued by the Drug Controller.
- 5.5. Valid manufacturing license issued by Central/ State Drug Controller indicating the list of products should be submitted. Public Sector Undertaking with at least "3-years" market standing having manufacturing license issued by Centre/State Drug Controller.
- 5.6. Valid Narcotic license issued by Central/ state Excise Commissioner should be submitted by the bidder.
- 5.7. Manufacturing firm should upload the scanned copy of performance certificate of 02 years for supply of Drugs/ Medicines/ IV Fluids within last 05 financial years i.e. 2017-18, 2018-19, 2019-20, 2020-21 & 2021-22 from any Government Hospital/ PSUs./ Institutions on the purchaser letter head where the bidders is supplying these items in reference to this tender. The performance certificate submitted should be issued within preceding one year from the date of the publication of the tender.
- 5.8. Valid GST Registration certificate & PAN
- 5.9. Turnover clause:
 - 5.9.1. Minimum annual turnover of the tenderer should be **₹30 crores** (Rupees Thirty crores only) or more in the last three financial years i.e. 2019-20, 2020-21, 2021-22 for Drugs.
 - 5.9.2. Group turnover (other than drugs and their formulations) will not be considered for determining the eligibility and such tenders will be rejected summarily.
 - 5.9.3. Balance Sheet & Profit and Loss account for the years 2019-20, 2020-21, 2021-22 duly certified by the Chartered Accountant/ Auditor. There should not be any negative balance.
 - 5.9.4. **Turnover for MSE Firms:** Participating MSE firms quoting for drugs shall have to fulfil the turnover criteria as defined for non MSE firms.

- 5.10. Bidders should upload the EMD receipt copy of e-procurement portal (EMD/ Bid Security of ₹1,00,000/- (Rupees One lakh only) for drugs.
 - 5.10.1. However, MSME/SSI units/ Udyog Adhaar Certificate/ Udyam Certificate holders are exempted from paying EMD/Bid security. However, they have to submit the **Bid Securing Declaration form** (Form-VIII) in ₹10/- affidavit stating that, they will not withdraw the bid.
 - 5.10.2. In case they are awarded the contract, they will have to submit the agreement and corresponding Security Deposit within 10 days failing which they are liable to blacklisting for 05 years.
- 5.11. If a tenderer is the sole manufacturer of the product, the same can be treated as a Proprietary drug, provided the firm submits a certificate to this effect from the statutory competent authority in India.
- 5.12. Non-Conviction Certificate issued by the Central/ State Drugs Controller to the effect that the manufacturer has not been convicted under the Drugs and Cosmetics Act, 1940 and rules there under during the last three years in respect of any of the drugs for which prices have been quoted by the tenderer. In case DCGI does not mention the name of the molecules in their certificates, a relevant undertaking will be provided with list of Drugs/ molecules along with non-conviction certificate, by the tenderer in addition to the above mentioned certificate. Non-conviction certificate must have been issued by the Drugs Controller of the concerned state within preceding six months from the date of the publication of the tender.
- 5.13. Certificate on self-attested non-judicial stamp paper of ₹10/- stating that there is no vigilance/ SBI case pending against the firm and the firm has not been blacklisted/debarred on the date of submission of the bid by any Central Govt./ State Govt. department/ hospital/ PSUs etc. bidder should also provide information regarding blacklisting/ debarring of the firm in last three years (2019-20, 2020-21, 2021-22) by any government or Private organisation/ Hospital. In case of any false information provided or concealed information by any bidder, the bidder shall be debarred for two years and EMD/Bid Security/ Performance Security submitted by the firm shall be forfeited.
- 5.14. Tenderer should also give a guarantee as follows, in case of biological and other products having a particular life-period to provide safe-guard against loss on account of deterioration within their stated period of potency.
 - "The manufacturer hereby declares that the goods/articles sold to the NIMHANS, Bengaluru under this contract shall be of the best quality and shall be strictly in accordance with the specification and particulars mentioned in the description clauses hereof and the manufacturer hereby guarantees that the said goods/articles would continue to confirm to their description and quality for a period of one year from the date of delivery of the said goods/articles or such portion thereof as may be discovered not to conform to their of the said goods/articles or such portion thereof as may be discovered not to conform to the description and quality. Such rejection of the goods/ articles will be at the manufacturers or their authorized supplier's risk and all the provisions herein contained relating to rejection of goods etc., or such portion thereof if rejected by the NIMHANS, Bengaluru shall be applicable. Otherwise the manufacturer shall pay to the NIMHANS such damages as may arise by reason of the breach of conditions herein contained. Nothing herein contained shall prejudice any other right of the purchase in that behalf under this condition or otherwise".
- 5.15. The manufacturer should give an undertaking to the effect that they will be legally bound to supply the medicines/drugs, for which they have quoted the

- rates in the tender during the validity of the contract and even in extension period also. In case, they fail to execute any purchase order placed to them within the agreed time period from the date of placement of purchase order, they will be liable for action against them as per tender terms.
- 5.16. Copy of list of items quoted as per annexure and manufacturer has to submit an <u>affidavit of ₹50/- (Rupees Fifty only) duly signed by the Notary</u> as under:
 - 5.16.1. "The pharmaceutical firm hereby declare that the drugs/items sold to the NIMHANS under this contract shall be of best quality and workmanship and shall be strictly in with the specifications and contained/mentioned in the description clauses hereof and the pharmaceutical firm/bidder hereby guarantees that the said drugs/items would continue to conforms to their description/ specification and the provisions of law as stated in the contract and that notwithstanding the fact that the NIMHANS officials may have inspected approved the said drugs/items. If the same be discovered not to conform to the description and quality aforesaid or have deteriorated, the decision of the NIMHANS in that behalf will be final and conclusive. NIMHANS will be entitled to reject said drugs/items or such portion thereof as may be discovered not to conform to the said description and quality in the manner as prescribed. Such rejection of the drugs/items will be at the seller's risk and all the provisions herein contained relating to rejection drugs/items etc. or such portion thereof if is rejected by the purchaser. Nothing herein contained shall prejudice any other right of NIMHANS in that behalf under this contract or otherwise".
 - 5.16.2. The Bidder submits stating that the drugs, which are being quoted, are not banned under Section 26 (A) of Drugs & Cosmetics Act. Or any other provision of law prevailing in India.
 - 5.16.3. It is declared that the firm/ company and any of its Director/ Proprietors/ Partners/ Authorized signatories are not convicted / a criminal case filed against or pending in any court of India by any department of Government of India and State Governments under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Govt. fund or any criminal conspiracy in the said matter
 - 5.16.4. The Bidder submits an undertaking that it is not submitting bid for any drug/ combination of drugs which is not approved by DCGI".
 - 5.16.5. Company/Authorised Signatory has to submit an affidavit giving address of Manufacturing units and their license numbers
- 5.17. For the drugs which are being imported, the manufacturing firm will submit valid import license issued by the Drug Controller General of India and valid Manufacturing Marketing Standard Certificate issued by concerned Licensing Authority (Form 10 & Form 41). That firm will be eligible if one batch of new drug has been imported at the time of bidding.

- 5.18. In case of patented drugs, manufacturing firm will submit valid certificate to this effect from the Licensing Authority else tenderers claim will not be considered.
- 5.19. The tenderer should not be convicted/ or a criminal case filed against or pending in any court of India by any department of government under prevention of Corruption Act or for cheating/ defrauding Govt./ embezzlement of Govt. fund or any criminal conspiracy in the said matter. Should submit an notarized affidavit to this effect.
- 5.20. For the drugs quoted in the tender enquiry, participating manufacturer will have to submit the sample on demand. If bidder fails to submit the samples within the period specified, the tender will be rejected.
- 5.21. Those firms that have not honoured the agreement in previous years, resulted in cancellation of purchase order and inconvenience to the Institute by defaulting on their supply are not allowed to participating in the tender.

6. FALL CLAUSES:

- 6.1. The price quoted shall not in any case exceed the maximum wholesale ceiling price (Bulk) if any, fixed by the Government of India/ National Pharmaceutical Pricing Authority (NPPA)/ State Government. The bidder shall mention such fixed rates in the quotation sheet against each item quoted.
- 6.2. The rate quoted for the Drugs supplied under Rate Contract, in no event shall be more than the lowest price quoted of which the bidder sells his products of identical description to any other persons, States, Union Territory, Corporation Board, University, Trust, Local Authority, Company or any others including his own dealer, distributor, stockist, agent during the period of the currency of the Rate Contract.
- 6.3. If at any time during the period of contract, the bidder reduces the sale price of such products to any other persons, States, Union Territory, Corporation, Board, University, Trust, Local Authority, Company or any others including his own dealer, distributor, stockist, agent during the period of the currency of Rate Contract at a price lower than the price quoted in this contract, he shall forthwith notify such reduction or sale to NIMHANS. The price payable under this contract shall correspondingly be reduced to the same extent as sold to such others. Under no circumstances the rate quoted shall be higher than the price notified under Drugs (Price control) Orders issued from time to time.
- 6.4. The bidder pleading for such price revision shall produce all the necessary comparative documents issued by the Competent Authority and shall also provide such additional information/documents, which the purchaser may desire for taking decisions.
- 6.5. Failure to notify the purchaser to pass on such benefits due to decreased GST or Exemption accorded shall entail disqualification of the Bidder and forfeiture of the security Deposit due if any.

7. SUBMISSION OF SAMPLES:

- 7.1. Samples of Drugs, Chemicals, Surgicals (Listed as Annexure C) are required to be submitted to the Pharmacy Main Stores of NIMHANS on or before last date for submission of the tender
- 7.2. Acknowledgement of samples provided list shall be uploaded in the e-procurement portal.
- 7.3. Cost of the samples shall not be payable by the Tendering Authority.
- 7.4. The samples submitted will not be returned to the bidder either on successful OR unsuccessful bidder under any circumstances

- 7.5. The drugs which have been manufactured as physician sample & other Institutional supply should not be furnished as sample.
- 7.6. Expired drugs will not be considered as samples (as on date of opening of the sample)
- 7.7. Sample should not depict MRP on the label.
- 7.8. If the intended supply is of IP/BP/USP, the sample also should correspond to that.
- 7.9. Sample submitted is final, no alteration, change of sampled items will be permitted. If any bidder/ tenderer is found altering the same, he will be liable to disqualification & will be blacklisted during tender period & EMD may be forfeited.

8. PACKING:

- 8.1. Tenderers must quote for the packing specified against each item in the schedule annexed to the rate-enquiry, as any other packing will not be accepted. Where no pack is specified, tenderer may quote for standard pack which is available in the market.
- 8.2. Drugs and Medicines shall be supplied in the package specification and package shall carry the logograms specified as "NIMHANS SUPPLY NOT FOR SALE" along with License Number, Batch No., Manufacturing Date & Expiry Date of Drugs. Otherwise, item will be rejected. Delaying supply due to Logograms will not be accepted.
- 8.3. Drugs requiring refrigeration or freezing for stability should specifically indicate the storage requirements on labels on each and every container and should be transported in appropriate containers to ensure stability in transit from the point of shipment to the destination.
- 8.4. The tenderer/bidder shall provide such packing for the goods including the outer bulk packs, as it requires preventing their damage or deterioration during handling and transit to their final destination as indicated in the orders.
- 8.5. Loose supplies/ damage packing / tampered or damaged labelled supplies shall not be accepted under any circumstances. Supplies to be made in the box of standard packing. However, tablets/ capsules in loose pack (tin/bottle) shall not be accepted.
- 8.6. The packing shall be strong enough to withstand, without limitation, rough handling during transit and exposure to weather conditions, prevailing in Karnataka state during transit and storage.
- 8.7. The goods shall be packed using virgin packing materials in such a manner as to ensure delivery in good condition. The supplies packed in used/ recycled containers will be rejected and such supply will be deemed as 'Sub-Standard' supply and such company will be liable to be blacklisted.
- 8.8. Supplies with smudged, corrected, over-written or masked labels due to whatever reason will be rejected. The logos printed should be such that they do not mask the contents of the label.
- 8.9. It should be ensured that only first use packing material of uniform size including bottle and vial is used for making supplies.
- 8.10. All primary packing containers should strictly conform to the specification included in the relevant pharmacopoeia and the Drugs and Cosmetics Acts and Rules.
 - 8.10.1. The labels in all case of injectable should clearly indicate whether the preparations are meant for Intra Venous (IV), Intra Muscular (IM) or Sub Cutaneous (SC) or Intra Dermal (ID) administration etc.
 - 8.10.2. Packs containing Ampoules shall be supplied with Ampoule cutters with every unit pack @1 cutter-file per 10 ampoules.

- 8.11. The shipper packing in cartons should be as per standard operation procedure. It should not exceed more than 25 KGs weight to enable easy handling.
- 8.12. In the event of items of drugs supplied found to be not as per specifications in respect of their packing, the tender inviting authority is at liberty to make alternative purchase of the item of drugs and medicines for which the purchase orders have been placed from any other sources in the open market or from any other bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the tender inviting authority has every right to recover the cost and impose difference in cost as penalty.

9. STANDARDS AND SPECIFICATIONS

- 9.1. Drugs should conform to the Pharmacopeia specifications. The drugs supplied shall conform to the quality standards including the standards specified for packing materials under the Drugs and Cosmetics Act and Rules framed there under. Minimum content of active ingredients should not be less than the labelled amount at the time of delivery of drugs.
- 9.2. The drugs shall be labelled as per provisions under Drugs and Cosmetics Act of 1940 and the Rules made there under. The size of the label shall be proportionate to the size of the container.
- 9.3. IV fluids supplied should be manufactured under form of Fill Seal technology in good quality polythene containers. Blood products should be supplied only after getting HIV and Hepatitis -B screening certificate by an independent approved laboratory. A copy of these certificates should be sent with every consignment and every invoice and also along with the samples provided.
- 9.4. Further, unless otherwise specified, all solid dosage forms should be in aluminium strips/ blister packing.
- 9.5. The blister packing should be either one side or both sides aluminium.
- 9.6. In case blister packing with one side aluminium is supplied, the other side should be of transparent poly material of sufficient strength.
- 9.7. The name of the item should be printed for every four tablets/ capsules on the strips or the name should run continuously along with the edge of the length of the strip to ensure identity on cutting the strip while dispensing.
- 9.8. The strip / blister pack should be effectively sealed to ensure protection of the tablet/ capsule from the atmosphere moisture.

10.EXPIRY DATE:

- 10.1. All products must indicate the Date of Manufacture and Expiry.
- 10.2. The stock should be supplied to this Institute from the latest batch and such a stock should have a minimum shelf-life period of 18 months. Depending upon the normal potency prescribed, supplies with a minimum life period of one year at the time of receipt will be accepted and bill will be passed only for the consumed quantity. Drugs with less than 3 months shelf-life in the stock of NIMHANS Pharmacy should be replaced by the supplier free of cost.
- 10.3. Replacement intimation should be sent to concerned before 03 months of date of expiry for product replacement.
- 10.4. In the event of such drugs not being utilized within their life period, the tenderer should undertake to replace the unexpended stock by fresh stock without demanding any extra cost.
- 10.5. Replacement should be made within 15/30 days from the date of intimation failing which, the equivalent amount will be recovered from the tenderer pending bills and/or Security Deposit.

11. TESTING OF DRUGS - QUALITY CONTROL:

- 11.1. Drugs, Chemicals, etc., supplied to the Institute should be of good quality and the decision of NIMHANS in this regard is final and binding on the Tenderer/Bidder. If the quality of drugs is not satisfactory and does not meet the Pharmacopoeia requirements and proper maintenance of cold chain, the same will be rejected and the supplied item has to be removed from the Institute by the Bidder/Tenderer immediately on their own expense after receipt of intimation. If the item is not removed within 30 days from the date of the intimation letter, the supplies will be destroyed. The drugs will not be returned to the tenderer and no claim will be entertained.
- 11.2. Purchaser reserves the right to test each batch or batches selected at random of the consignment received either at the time of receiving the goods or at any time during the shelf life of the product for test and analysis at any laboratory approved under the Drugs and Cosmetics Act and Rules notwithstanding the routine sampling that may be carried out by the Drugs Control and Regulatory authorities. Handling at the rate of ₹500/- per batch and testing charges as per actuals will be deducted by NIMHANS for the above purpose from the respective manufacturer.
- 11.3. Each batch of supply should be accompanied with the copy of Certificate of Analysis (COA) from the Government approved drug testing laboratories as per CDSCO.
- 11.4. If the sample or samples is/are declared to be "NOT OF STANDARD QUALITY" or "SPURIOUS" or "ADULTERATED" or "MISBRANDED", such batch/ batches will be deemed to have been rejected. If the samples do not conform to the statutory standards, the bidder will be liable for relevant action under the existing laws including prosecution.
- 11.5. In case a batch tested is declared as "Not of Standard Quality", the Bidder shall supply a fresh stock of "Standard Quality" equivalent to the entire quantity of the batch supplied earlier, irrespective of the quantity available in stock, within 30 days from the date of receipt of such communication.
- 11.6. If any written complaints are received from the user departments regarding the quality of drugs, the item will be rejected. Order will be placed with next lowest tenderer. No payment will be made even for the consumed quantity and the tenderer will be blacklisted for TWO years to trade with the Institute.
- 11.7. In case of poor quality of items supplied, the name of the tenderer as well as the details of quality control failure will be displayed on the web page of NIMHANS.
- 11.8. Any violation of tender norms may lead to blacklisting of the tenderer by the Institute for 3 years.

12.WARRANTY:

The items to be supplied by the tenderer shall be as per the formulations/standards approved/ specified by the NIMHANS or as per the regulations of any such statutory authorities. The manufacturers shall be held responsible for the consequences of supplying any sub-standards or spurious and adulterated drugs or medicines not conforming to such regulations/ Acts.

13. VALIDITY OF QUOTATION:

The rates quoted shall be valid for 12 months from the date of agreement entered with NIMHANS. The validity period may be extended additionally up to one year at the discretion of the Director, NIMHANS.

14. ORDERS AND DELIVERY SCHEDULES (SUPPLY CONDITIONS):

- 14.1. Orders will be placed with the selected tender parties and payment will be made to them directly through ECS as per Government rules.
- 14.2. Purchase orders placed against the contract, on or just before last date of the tenure of contract will have to be accepted/ honoured by the manufacturers.
- 14.3. The purchaser does not guarantee the quantity, which will be ordered. The quantity mentioned is only the tentative requirement and may increase or decrease as per the actual requirement. No claims shall pay against NIMHANS in this regard. The rate quoted should not vary with the quantum of the order.
- 14.4. The tenderer should intimate this office about the supply position within 05 days from the date of purchase order, failing which, it would be considered that the tenderer is not interested in executing the supply against the order and the purchase order will be awarded to the next lowest tenderer.
- 14.5. In case the selected company wants to supply and raise the bills through their authorized distributor, the name, address and contact telephone number should be given during the agreement and is shall be entered in the agreement. Further modifications will not be entertained. In extraordinary situation it may be permitted after the approval from the Competent Authority. In such case the companies are requested to supply directly from company.
- 14.6. The purchaser reserves the right to order for only such quantity as may be necessary and the Bidder is bound to supply the ordered quantity only. Quantities supplied in excess will not be paid for.
- 14.7. The Bidder is permitted to supply the ordered quantity in phases not exceeding two:

<u>PHASE-I:</u> Deliveries should be made with not less than 50% of the quantities of each item ordered within 15 working days or the period entered in the agreement from the date of receipt of the purchase order

<u>PHASE-II</u>: The remaining quantity of each item ordered should be delivered within another 15 working days or the period entered in the agreement.

- 14.8. Each carton container to be supplied to NIMHANS shall be embossed/ stamped with "NIMHANS PHARMACY", by the manufacturer at their own cost.
- 14.9. Supply time: Timing 10:00AM to 03:30PM on all working days
- 14.10. Successful bidders and their authorised suppliers (if any, as entered in the agreement) must always keep a reasonable quantity along with analytical test report to ensure to supply within 24 hours of telephonic orders (in case of critical and life-saving drugs)
- 14.11. The strip and the packing should clearly state the name of the manufacturer who has participated in the tender.
- 14.12. Special drugs wherever strip pickings are not available will be accepted.
- 14.13. The order will be awarded to the successful tenderer for the supply of Drugs for the specified period and the tenderer shall supply on receipt of purchase orders from the Assistant Administrative Officer (H), Hospital Staff Section. A scanned copy of purchase orders will be sent to the email of the manufacturer / authorised supplier
- 14.14. The lead time is shall be entered in the agreement copy and shall be within 30 days for Non-Narcotic Drugs and 45 days for Narcotic Drugs.
- 14.15. All I.V. fluids unless otherwise indicated should be manufactured using FFS technology. The bottles should be well packed in sturdy boxes to withstand stacking and transport. If packing is not satisfactory and the cardboard boxes are flimsy, the supply will be rejected.

- 14.16. Bandages/ POP bandages will be tested in the Institute and only those items which are found to be of good quality and suitable will be included for selection. No reason will be given for rejection.
- 14.17. Proper maintenance of the cold chain during transit is essential. Packages received without proper cool packs and whose temperature is not within stipulated range will be rejected.
- 14.18. Supply of IV fluids should be in truck having fixed metallic roof to avoid damage during transit.
- 14.19. As far as possible supply should be made from single or minimum number of batches. Separate batches should be packed separately.
- 14.20. Packing slip containing full details about the contents like Quantity, Batch number, Manufacturing Date and expiry date should be pasted on every parcel.
- 14.21. Ampoules should be supplied with aluminium files for breaking them. Each pack should contain 5 files.
- 14.22. The company should ensure that the size of the letter font in the strips of the tablets capsules and in the vials and ampoules of the injections should be readable and visible to enable the Pharmacists / Doctors / Patients to identify the drugs without difficulty failing which the drugs will be rejected.
- 14.23. The company should ensure that the drugs supplied by them should be of different strip colour and size. If NIMHANS receive any lookalike drugs with same strip colour and size, the supply will be rejected and purchase will be initiated from the next lowest supplier. The difference in cost (Minimum ₹2,000/-) will be recovered from the defaulted company.
- 14.24. Manufacturers shall arrange to effect free replacement of any quantity which may deteriorate in potency, strength approaching expiry or expired etc. before the date of expiry marked on the labels.
- 14.25. If the supplied item is not utilised before expiry date the supplier or manufacturer should undertake to replace with fresh stock of items as and when required.
- 14.26. Purchase orders will be sent through email followed with speed post. The tenderers are requested to give their correct postal address and valid email ID to enable the delivery of purchase orders. Further they are requested to check the mail regularly.
- 14.27. For Disinfectant and Chemicals, the supply has to accompany with MATERIAL SAFETY DATA SHEET (MSDS) containing information on physical and chemical properties of the material, potential hazards and exposure control measures, information on safe handling of these materials, information on usages, storage, handling and emergency procedures relate to the hazards of the materials.
- 14.28. **MARKING:** Each packing shall be marked with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under.
- 14.29. Manufacture is primarily responsible for ensuring the supply of consignment within stipulated time frame and procedures as decided.
- 14.30. The Institute has right to intimate manufacturer to change the supplier if there is a reason for the Institute to believe so.

15.PENALTY CLAUSE:

- 15.1. In case the supply is not completed fully within the stipulated period (30 days) as mentioned above, the purchaser reserves the right to cancel the order for non-supplied quantity and proceed with the purchase of the same generally identical item from L-II or L-III (if specified in the Rate Contract) or from the open market in the order of preference.
- 15.2. If the supply is not made within the time specified in the purchase order, then **NIMHANS** reserves the right to procure the drugs of similar nature from the next

- alternative lowest choice manufacturer/ open market and the extra expenditure incurred will be recovered from the manufacturers Performance Security / Security Deposit / suppliers bill along with administrative cost of 20% of the value of the purchase requisition (minimum of ₹2,000/-).
- 15.3. The difference of cost (minimum of ₹2,000/-) due to purchase from the next alternate source like L-II, L-III (if specified in R.C.) or open market in the same order preference shall be recoverable (along-with 20% of administrative cost) from the Manufacturer / Supplier as under:

Difference of cost between L-I and L-II from L-I
Difference of cost between L-II and L-III from L-II
Difference of cost between L-III and open market from L-III

In case L-II and/or L-III are not specified in the Rate Contract, the difference of cost shall be recovered from L-I with reference to the purchase price as the case may be.

15.4. Penalty for late supply:

- 15.4.1.Manufacturer and their authorized supplier fails to execute the purchase order within the stipulated time / period as entered in the agreement, a penalty of 0.5% per day + GST, maximum 10% + GST unless extension is obtained in writing with valid grounds/ reasons. Such extension is permissible for a maximum period of 3 weeks only. That extension of delivery period cannot be claimed as a matter of right but will be at the discretion of the Competent Authority.
- 15.4.2.If the manufacturer firm fails to execute the purchase order three times during the period of rate contract, without written permission from the Competent Authority of NIMHANS, it shall be debarred for the next three years with effect from the last failure and forfeiting of EMD/Performance Security for that drug.
- 15.5. The approved manufacturers should supply all their ordered items within Date of Delivery (DOD) period as per Purchase Order terms and these terms should be strictly adhered to. In case they fail to supply the item within DOD period, the reminder letter would not be issued in any circumstances and penalty will be imposed. The item would be arranged with other through local purchase or from open market under Risk Purchase Clause without any information in this regard. The difference amount shall be recovered from the pending dues of the firm. In the eventuality of such instances being repeated, administrative action shall be initiated as per NIMHANS procedure which may lead to debarring of the firm for subsequent tenders (up to 3 years)
- 15.6. It is hereby also informed that in case any administrative action (imposing of liquidated damages, warning letter, risk purchase, short supply etc.) is taken by the NIMHANS during the tender period against any approved tenderers, it would be reflected during finalization of the next tender as "Past Performance" of that firm.
- 15.7. The Director, NIMHANS or her nominee reserves the right to invite at her sole discretion, separate quotations to effect purchase outside this contract in the event of any urgent demand arising in hospital, where no stock is held or otherwise.
- 15.8. When the total penalty amount exceeds the EMD/SD held, the firm has to remit the amount failing which the firm will not be allowed to participate in the next tender.

16.PAYMENT CLAUSE:

- 16.1. 100% payment would be made on receipt of goods in good condition and acceptance upon the submission of the "Original copies of suppliers invoice showing Purchase Order number, goods description, quantity, packing list, unit price and total amount"
- 16.2. No advance payment will be made towards the supply. Payment will be made only after the items are supplied as per the purchase order/supply order
- 16.3. Payments towards the supply of drugs & chemicals will be made strictly as per rules of NIMHANS, Bengaluru
- 16.4. Any dues or payment that have arisen to the Institution from the manufacturer or their authorised suppliers for which no specific time-limit has been laid down in the terms & conditions, shall be payable by the manufacturer or their authorised supplier within such time limit as may be prescribed in the various letters/orders addressed to the manufacturer/tenderer/contractors. On failure to do so the manufacturer or their authorised supplier shall be liable to be debarred for not paying dues or payment etc. to the hospital for a period as decided by the Director or her/his nominee.
- 16.5. Condition of advance payments shall not be entertained.
- 16.6. No claims shall be against NIMHANS, Bengaluru, in respect of interest on Earnest Money Deposit or on Security Deposit or Delayed payments.

17.RIGHT TO TERMINATION OF THE CONTRACT

- 17.1. The purchaser may without prejudice to any other remedy for breach of Terms and Conditions of tender, by written notice of one month shall terminate the contract whether in whole or part, stating reasons thereof.
- 17.2. During the period of agreement if it is found that the tenderer or its authorised supplier is not providing proper supply of the ordered items within specified time period, NIMHANS reserves rights to make the vendor forfeit the security deposit deposited with NIMHANS or part thereof in favour of NIMHANS and agreement will be terminated after giving 30 days' notices. Furthermore, in such situations, tender can be allotted to the second lowest bidder and the difference in cost shall be recovered from the earlier vendor who is in breach of the contract. In addition, in case it is found that the supplier is charging by fraudulent means or indulging in criminal activities, the contract will be terminated immediately.

18. **DISPUTES AND JURISDICTION**

In the event of any dispute arising out of the Terms and Conditions of the tender, such disputes would be subject to the jurisdictional courts in Bengaluru, Karnataka.

19.BLACKLISTING CONDITIONS:

The purchaser reserves the right to blacklist any tenderer/ bidder for the following reasons.

- 19.1. If the bidder(s) fail to supply two or more times within the stipulated period of 30 days during the tender period, the EMD of the tenderer/ bidder will be forfeited to NIMHANS, in addition to the recovery of the penalty involved for the above purchase (Recurring in delay of supplies)
- 19.2. Further the bidders/tenderers will also be blacklisted for 3 years to trade with this Institute. Details of such blacklisted by the Institute will be put up in the Institute website. The same will be informed to similar government procurement agencies.
- 19.3. Abnormal under-quoting
- 19.4. Non-executing of agreement and not making Security Deposit within the stipulated time when his offer is accepted

- 19.5. Submission of false documents
- 19.6. Supply of spurious Drugs.
- 19.7. Supply of substitutes other than the approved sample
- 19.8. Manufacturers who have been notified as BLACKLISTED by the Central/ State Government/ any Drugs procuring agencies/Institutes are not eligible for participating in this tender. Such tenders will be rejected even if received. If the Tendering Authority comes to know such BLACKLISTED status of the firms subsequent to the opening of the tender/acceptance of tender, awarding of the Contract, all the deposits and dues of the Tenderers/Bidders shall be forfeited to NIMHANS and such firms will be liable for BLACKLISTING for 3 years.
- 19.9. NIMHANS reserves the right to reject the Tender of the Blacklisted companies/firms whose past performance with NIMHANS on any similar agencies was poor due to delayed and erratic supplies, frequent quality etc.
- 19.10. Any violation of tender terms and conditions may lead to blacklisting of the bidder/tenderer by the Institute initially for one year and followed by 3 years
- 19.11. In case of continuous default in supply, non-supply of drugs the Drug Purchase Committee (DPC) of NIMHANS will debar the bidder for one year
- 19.12. If a company is blacklisted for more than two times, the Drug Purchase Committee (DPC) of NIMHANS will recommend to Blacklist the firm for a further period of 15 (fifteen) years.

20. SPECIAL CONDITIONS.

- 20.1. ALL GLASS BOTTLES SHOULD BE OF NEW NEUTRAL GLASS WHEREVER POLYPROPYLENE HAS BEEN PRESCRIBED. IT SHOULD BE PROVIDED SO.
- 20.2. ALL LIQUID ORALS SHOULD BE PROVIDED WITH MEASURING DEVICE
- 20.3. INJECTION IN VIALS SHOULD HAVE A SNAP OFF SEAL
- 20.4. THE STRIP SHALL BE ALUMINIUM & ALL STRIPS/ BLISTERS SHALL BE WITH ALUMINIUM FOIL BACK
- 20.5. EVERY CONSIGNMENT OF BLOOD & RELATED PRODUCTS SHOULD BE CERTIFIED TO BE

 a) HIV FREE

 b) HEPATITIS-B FREE
- 20.6. ALL SUPPLIES SHOULD ACCOMPANY ORIGINAL DELIVERY NOTE OR INVOICES
- 20.7. PHOTOCOPIES/ FAX COPIES OF THE DELIVERY NOTE OR THE INVOICE WILL NOT BE ACCEPTED.
- 20.8. GOOD NON-ABSORBABLE PAPER SHOULD BE USED FOR THE DELIVERY NOTE AND INVOICES.
- 20.9. THE MATTER PERTAINING TO THE SUPPLIES SHOULD BE EITHER PRINTED OR TYPEWRITTEN OR LEGIBLY HAND WRITTEN ON THE DELIVERY CHALLAN OR THE INVOICE.
- 20.10. THE DELIVERY CHALLAN OR THE INVOICE SHOULD NOT CONTAIN ANY MATTER ON ITS REVERSE SIDE
- 20.11. THE LABEL OF THE ITEM SUPPLIED UNDER THE CONTRACT SHALL NOT CARRY THE M.R.P.
- 20.12. THE TENDERER WILL INVARIABLY INSCRIBE IN EACH SUPPLY, "NIMHANS SUPPLY NOT FOR SALE". OTHERWISE, ITEM WILL BE REJECTED. DELAYING SUPPLY DUE TO THIS REASON WILL NOT BE ACCEPTED.
- 20.13. THE GENERIC NAME OF THE ITEM SHOULD BE AS BOLD AS THE TRADE NAME, IF ANY
- 20.14. THERMO-SENSITIVE DRUGS WHICH ARE TO BE STORED IN REFRIGERATORS SHOULD BE SUPPLIED UNDER SUITABLE COLD CHAIN SYSTEM ONLY.
- 20.15. ONLY PERMITTED COLOUR OF THE AMPOULE/VIAL SHOULD BE USED.

- 20.16. ALL DOCUMENTS OF DRUGS MOVEMENT LIKE DELIVERY NOTE CHALLAN, BILL/INVOICE SHOULD CARRY THE GENERIC NAME WITH TRADE NAME IF ANY, MAKE, BATCH NUMBER and EXPIRY DATE.
- 20.17. NIMHANS RESERVES THE RIGHT TO PURCHASE THE ITEMS OVER & ABOVE THE QUALITY MENTIONED IN THIS DURING THE CONTRACT PERIOD.
- 20.18. IN ALL THE ABOVE CONDITIONS, THE DECISION OF THE DIRECTOR, NIMHANS, BENGALURU SHALL BE FINAL AND BINDING.

-Sd-DIRECTOR

FORMATS TO BE ATTACED TO THE TENDER

<u>ANNEXURE – A</u>

TENDER OFFER FORM

No. NIMH/PU-I(D)/TENDER/RC(23-24)/01/2022-23, DATED:09.01.2023

To The Director, NIMHANS, BENGALURU – 560 029. Affix the photograph with self-attested.

Sir.

I/We have examined the tender documents in connection with the supply of Drugs, Chemicals & Surgicals items of your Institute under Rate Contract for the year 1st April 2023 to 31st March 2024 called by you. I/We, the undersigned offer to supply and deliver the Drugs, Chemicals & Surgicals items in conformity with the terms and conditions of the tender at the rates quoted in the Annexure if the contract is awarded in my/our favour.

I/We understand that the quotation offered shall be valid for a period of 12 months from the date of finalization of the contract which may further be extended by another three to six months if required by you.

I/We undertake if our quotation is accepted, I/we will enter into contract to deliver the goods in accordance with the delivery schedule.

I/We agree to abide by this tender for the period up to the end of March, 2024 or extended period.

I/We undertake to deposit Security Deposit amount in accordance with the terms and conditions of the tender if our offer is accepted.

I/We understand that you are not bound to accept the lowest or any quotations you may receive.

Signature of Authorized signatory

Name in Capital:

Capacity:

Seal of the firm:

Place : Phone No. Fax No. Mobile No.

Name & Address:

- i Official Address:
- ii. Residential Address:

Note:

Date:

- 1. The quotations shall be indicated in the format attached
- 2. Quotations not in the format will be rejected. Please indicate the designation and enclose the authority of the person signing the document.

ANNEXURE – B

CHECKLIST

No. NIMH/PU-I(D)/TENDER/RC(23-24)/01/2022-23, DATED:09.01.2023(**TO BE FILLED BY TENDERER**)

| Name of the Manufacturer: | |
|---------------------------|--|
|---------------------------|--|

List of documents to be enclosed along with the tender for supply of Drugs, Chemicals and Miscellaneous items to NIMHANS for the period 1st April 2023 to 31st March 2024.

| SI. | Name of the Document | Yes (Y) or | Document | Page No. |
|-----|--|---------------------------------|------------|----------------------------|
| No. | | No(N) or Not Applicable (NA) | No. & Date | (should not be left blank) |
| 1 | Copy of online payment receipt of Earnest Money | Applicable (NA) | | be left blank) |
| - | Deposit (EMD) Drugs, Chemicals & Surgicals ₹1,00,000/- | | | |
| 2 | GST Registration certificate | | | |
| 3 | PAN No. and copy enclosed | | | |
| 4 | Annual Turnover statement for the preceding three years (2019-20,2020-21,2021-22) | | | |
| 5 | Balance Sheet and Profit & Loss Account for the | | | |
| | preceding three years (2019-20,2020-21,2021-22) | | | |
| 6 | Manufacturing Licence up to date copy with attestation | | | |
| 7 | "No Conviction Certificate" issued by the Drug Controller | | | |
| | of the state/ appropriate authority in Original, issued not | | | |
| | more than one year ago from the date of opening. | | | |
| 8 | List of samples submitted | | | |
| 9 | Scheduled M or WHO-GMP Certificate issued by the Drug | | | |
| | Controller / appropriate authority in Original / Notarized copy | | | |
| 10 | In case of IMPORTED items: | | | |
| | a) Copy of valid Import Licence | | | |
| | b) Notarized copy of Registration certificate issued by the Drug Controller General of India, New Delhi. | | | |
| | c) Valid WHO-GMP certificate | | | |
| 11 | Affidavit of non-judicial stamp paper regarding Non-Black | | | |
| | listing of the firm or any of its products by any (should be | | | |
| | notarized) | | | |
| 12 | Declaration of the bidder as per | | | |
| | Form-II, Form-XI and Annexure-A | | | |
| 13 | Notarized affidavit as mentioned in Form-I | | | |
| 14 | Proforma/ checklist of quoted items as per Form-IV | | | |
| 15 | If any other documents | | | |

| SI. | Contents | Details |
|-----|--|------------------------|
| No. | | (Should be Typed only) |
| 1 | Complete Mailing Address along with Pin Code | |
| 2 | E-mail ID | |
| 3 | Contact No. (with STD Code) | |
| 4 | Mobile No. | |
| 5 | Fax No. (with STD Code) | |

Signature of Authorized signatory

Name in Capital:

Capacity:

Seal of the firm:

(Each certificate/ page should be signed by the bidder, along with their name, official designation and official stamp of firm)

^{**} This document should be upload in Technical Bid.

| FΩ | R | M | <u> </u> | ŀ |
|----|---|-----|----------|----|
| | | IVI | _ | ١. |

(To be submit in ₹10/- stamp paper)

| Notarized | <u>affid</u> | avit |
|------------------|--------------|------|
|------------------|--------------|------|

| I _ | | | Mar | | ctor/ Partner/ Proprietor of |
|----------------|-------------------|--|-----------------------------|--------------|------------------------------|
| M/s | | Managing Director/ Partner/ Proprietor of having its manufacturing or import unit/ registered do hereby declare that our company/ applied items have not | | | |
| office at | t | do he | ereby declare that | our compan | y/ applied items have not |
| | | | | | organization or its drug |
| procure | ment agencies f | for the follow | ving products quot | ed in the te | nder during last three (3) |
| | | | in the tender ref. No | | for supply of |
| | | xure C to NI | MHANS, Bengaluri | | |
| | We | | | h | ereby submit the tender |
| applicat | ion for supply of | Annexure (| S listed items | | |
| SI. No. | Drug Code | Name of th | e Drug | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| 1 | | | | | |
| | | | | | |
| 1 | | | | | |
| | | | | | |
| | | | | | |
| Fur | ther, I/ We decla | are that, this | firms having the ma | anufacturing | units as listed below: |
| SI. | Address | of the | Contact person | including | License No. |
| No. | manufacturing ι | unit | mobile No. & Tele | phone No. | |
| 1. | | | | | |
| 2. | | | | | |
| 3. | | | | | |
| | | | | | |
| | | | | | |
| (Company Seal) | | | Signature of the Proprietor | | |
| | | | N | Managing Pa | artner/Director |
| | | | N | ame : | |
| | | | | eal : | |
| Г | Date : | | 0 | J | |
| | Place : | | | | |
| • | | | | | |

Note: The above declaration, duly signed by the authorized signatory of the company, should be enclosed with the bid. The authorized signatory must be not below the rank of Manger.

FORM- II:

ACCEPTANCE OF THE TERMS & CONDITIONS

(To be filled by the Bidder and submitted with the tender)

| То |
|---------------|
| The Director, |
| NIMHANS, |
| Bengaluru-29 |

Sir/Madam,

We return herewith your tender Notification No. NIMH/PU-I(D)/TENDER/RC-2023/01/2022-23, DATED:09.01.2023 with our quotation against respective items. We have carefully gone through the Terms & Conditions of the Rate Contract and accept the same.

For and on behalf of the firm (Firm's Name & Address)

(Signature of Authorized Signatory)

Witness:

(Signed in my presence)

Name : Designation : Seal :

Notary Public:

(With Name & Complete Address)

FORM-III:

MANUFACTURER'S AUTHORISATION FORM (Letterhead)

The Director, NIMHANS, Bengaluru-29

Full Address:

Email ID

Landline No...... Mobile No.....

Dear Madam/Sir, Sub.: Authorization for local supplier/Distributors- Reg. Ref.: Tender Notification No. NIMH/PU-I(D)/TENDER/RC-2023/01/2022-23, DATED:09.01.2023 We, M/s, who are established and reputable manufacturers of Drugs, Chemicals, Surgical & Miscellaneous (Annexure-C) items, having factories/ Officer : and register office at, having Phone No. Mobile No. email ID..... For correspondence do hereby authorized to supply of approved/selected items as follows: Name of the Local Distributors/Supplier/Stockiest. Complete Address: Contact Details: Landline No....., Mobile No..... Email ID To supply materials and to collect the payment for the items guoted and concluded the contract by M/s....., with you against selected items under Annexure-C manufactured by us. No company/firm/individual other than M/s....., is authorized to supply the above goods manufactured by us against this specific tender. We hereby extended our full guarantee and warranty as per terms and conditions of the tender notification for the items offered for supply against this Rate Contract tender by the above firm, failing which the items shall be procured from the next alternative source and the cost difference to be recovered from above authorized supplier/distributors immediate bills. Kindly arrange to place the purchase orders to them for the items awarded to us against your requirement from time to time for entire tender period and make the payment directly to them against the supplies on behalf our firm. Thanking you, **Authorized Signatory** (Name of the person:

FORM- IV:

PROFORMA / CHECKLIST OF QUOTED ITEMS

| SI. No. | Drug code | Name of the Drug | Manufact uring Licence | Manufactu ring company | Brand Name | Drug Licence/ Import Licence Number & Page No. of the document | Validity up to (DL/ Imp. Licence) | WHO-GMP/ Schedule-M Certificate (Page No.) | Validity up to (WHO- GMP/ Schedule-M certificate) |
|------------|--------------|------------------------|------------------------------|------------------------------|---------------|--|--|---|---|
| 1 | | | | | | | | | |
| 2 | | | | | | | | | |
| 3 | | | | | | | | | |
| 4 | | | | | | | | | |

Strict compliance:- All the tenderers are directed to mention the page number of the tender document where WHO-GMP/ Revised Schedule 'M' & page number of manufacturing license for indigenous drugs/ import license for imported drugs enclosed. Merely mentioning the word "Enclosed" may lead to rejection of tender/ bid submission

Signature of Authorized Signatory

FORM - V:

MANUFACTURING & MARKETING STANDING CERTIFICATE

This is to certify that M/s ----- are holding valid Manufacturing

| licence | No | | dated | of the |
|----------|---------------------|-------------|-----------------------------------|--------------------|
| | | state and | they are manufacturing and market | ing, the following |
| products | s for last three (3 | 3) years. | | |
| The | e Products are a | as follows: | | |
| SI. No. | Name of | the Product | Pharmacopoeia Specification | Strength |
| 1. | | | | |
| 2. | | | | |
| 3. | | | | |
| 4. | | | | |
| 5. | | | | |
| 6. | | | | |
| 7. | | | | |
| 8. | | | | |
| 9. | | | | |
| 10. | | | | |

Signature and seal of Drug Controller of the Central/State.

Dated:

Note: This certificate is to be signed by the Drug Controller of Central/State. Certificate issued by the Inspector of Drugs will not be accepted unless an authorization by the concerned central/state Drug Controller to this effect is supported by adequate documentary proof.

FORM -VI:

NON-CONVICTION CERTIFICATE

| | It is certified that M/s | situated at |
|-------|--|--|
| | are holding valid drug | manufacturing license No |
| valid | till | |
| | | |
| | This firm has not been convicted under Dru | g & Cosmetic Act, 1940 and rules there under |
| in | State. | |
| | | |

State Drug Controller, Certifying & Licensing Authority

Name of the Official: Official stamp

FORM -VII:

Format of FFS Technology certificate

| No. | | Date: | |
|-----|--------|--|--|
| | | /shave been granted license in the form No | |
| | | nanufacture the following preparations | |
| | SI. No | Name of the Preparations | |
| | 1. | | |
| | 2. | | |
| | 3. | | |
| | 4 | | |

It is further certifies that the said manufacturer use FFS (The whole operations of Form, Filling and Sealing occurs simultaneously on the same machine in single cycle) technology in the manufacture of above preparation.

Signature & seal of Certifying Authority

FORM -VIII:

Bid Securing Declaration form

(To be submitted by the EMD/ BS exempted firms only)

To The Director, NIMHANS, Bengaluru-29

Sir,

I/We, the undersigned, declare that:

I/we understand that, according to your conditions, bid must be supported by a Bid Securing Declaration.

I /We accept that I/we may be disqualified from bidding for any contract with you for a period of 05 years from the date of notification if I am /We are in breach of any obligation under the bid conditions, because I/We

- a) Have withdrawn/modified/amended, impairs or derogates from the tender, my/our Bid during the period of bid validity specified in the form of Bid; or
- b) Having been notified of the acceptance of our Bid by the NIMHANS, Bengaluru during the period of bid validity (i) fail or reuse to execute the contract, if required, or (ii) fail or refuse to furnish the performance Security, in accordance with the instructions to Bidders.

I/We understand this Bid Securing Declaration shall cease to be valid if I am/We are not successful Bidder, upon the earlier of (i) the receipt of NIMHANS notification of the name of the successful Bidder; or (ii) thirty days after the expiration of the validity of my/our Bid.

Signature of the official Designation Name (in capital) Corporate seal

(Note: in case of a Joint Venture, the Bid Securing Declaration must be in the name of all partners to the Joint Venture that submits the bid)

FORM -IX

ANNUAL TURNOVER STATEMENT

(In the letterhead of the Chartered Accountant)

| The Annual Turnover for the last three financial years of M/s | who |
|--|-----|
| is a manufacturer / bidder for Drugs/Chemicals, Surgical and Miscellaneous items as publis | hed |
| in NIMHANS, as per audited Financial Statements are given below and certified that | the |
| statement is true and correct to the best of our knowledge and belief. | |

| SI. No. | Financial Year | Turnover in Crores/Lakhs (Rs.) both in figures & words |
|---------|----------------|--|
| 1 | 2019-2020 | |
| 2 | 2020-2021 | |
| 3 | 2021-2022 | |

Date : Place :

Signature of Auditor/ Chartered Account (Name in Capital)
Seal
Membership No.

Note:

This turnover statement should also be supported by copies of audited annual statement of the last three financial years/Annual Report and the turnover figures mentioned above should be highlighted there.

FORM-X:

PRICE BID FORMAT

| SI. No. | Drug Code | Name of the Item | Manufacturer Name | Brand Name | Unit | Unit Price / Offered (in figures) | Unit Price (in words) | GST Rate (in %) | Total Unit Price with GST (in INR) | MRP / Retail sale price | Remarks |
|------------|--------------|------------------------|----------------------|---------------|-----------|---|---|---------------------------------|--|-------------------------------------|---------|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| | | | | | | | | | | | |
| 1 | AA | AA | BBB | AA | 1 Tab. | ₹2.66 up-to two decimal places | Rs. Two and paise six six only | 0% / 5% / 12% / 18% | | | |
| 2 | BB | BB | AAA | BB | 1 Inj. | ₹15.90 | Rs. Fifteen and paise ninety | 0% / 5% / 12% / 18% | | | |

Instructions for filling this:

^{*} Unit means : per Tablet, Injection, Ampoule, Bottle, Litre etc.

** "Retail Sale Price" means the retail price displayed by the manufacturer under the provisions of the Drug (Price Control) Order 2013 applicable from time to time.

^{***} For column No. 9 please entre

⁻ NIL/ 5% / 12% / 18% - as applicable.

I.

II.

PROFORMA TO BE FILLED BY THE TENDERER

| _ | Name of the firm | : | | | | |
|----|--|--------------|--|--|--|--|
| b. | Address & Telephone No. | : | | | | |
| C. | Whether the firm is Indian/ Multi-national | : | | | | |
| d. | Whether Small/ Medium/ Large Scale Com. | : | | | | |
| e. | Person responsible for conduct of Business | : | | | | |
| | Particulars of Licenses held under Drugs & Cosmetic Act & the details. (if the license is under renewal, certificate from the Drug Controller that the license is under renewal and deemed to be enforced) | | | | | |
| g. | Has the firm been convicted ever, if yes, give d | etails : | | | | |
| h. | Any care pending in the court with details | : | | | | |
| | . Has the firm ever been debarred / black- listed by any Government Hospital/ organization for poor quality or late supply of Drugs? If yes, give details. | | | | | |
| j. | Fax No. : | | | | | |
| k. | E-mail address : | | | | | |
| | Name & Mobile No. of person/ authorized signatory to be contracted for this tender : | | | | | |
| a. | CHNICAL Equipment's for material handling, manufacturi and quality control of drugs | ing of drugs | | | | |
| | Specialized testing facilities such as mic testing and Biological testing : | robiological | | | | |
| C. | Details of Technical Staff : | | | | | |
| | i. Manufacturing Staff : ii. Quality control staff : | | | | | |

| | | Has the firm carried out stability study for drugs quoted : |
|---------------|----------|--|
| | e. | Is the firm basic manufacturer of the drug quoted, if yes |
| | f | details : Has the firm following |
| | ١. | i. WHO-GMP Certificate/ Schedule-M : |
| | | ii. ISO Certificate |
| | | iii. FDA Certificate : |
| | | iv. Import License : |
| | a | Installed capacity and actual production details for different forms of drugs : |
| | 9. | i. Tablets |
| | | ii. Capsules : |
| | | iii. Syrups/ Suspension: |
| | | iv. Injections : |
| | | v. Powder : |
| | | vi. Inhalation : |
| | | vii. Topical : |
| | h | Drugs declared and sub-standard/ re-called during the last three years. Give |
| | ••• | details with reasons and the remedial action taken : |
| | | |
| | | |
| III. | FIN | IANCIAL |
| ; | a) | Turnover during last three financial years (year wise) of the pharmaceutical |
| | | products. Firms should furnish copies of audited Balance Sheet/ Sale Tax |
| | | clearance certificate. |
| | | |
| | b) | Name & Address of the Bankers to the Firms and the facilities available from the |
| | | bank. |
| | | |
| • | c) | GST Registration No. : |
| | d) | PAN No. : |
| | , | |
| | | |
| DECL | .AR | ATION |
| | | Duamistan/ Danta and Dina stan of M/s |
| l, | | Proprietor/ Partner/ Director of M/s |
| | | re that the information given in this form is true and correct to the best of my |
| knowledge | e ai | id belief. |
| | | |
| | | Signature |
| | | (Name & Designation with stamp) |
| /// A DNIINIC | <u>.</u> | If the information furnished in this form is found to be incorrect at any point of time |
| ANUMINI | ٠. | If the information furnished in this form is found to be incorrect at any point of time, |

۷ the tenderer may be debarred.

Annexure-C

| | in r/o Drugs, Chemicals, Surgical and Miscellaneous ite | ms under Ra | ate Contra | ct year 2023-24 | | | |
|--------------|--|--------------|---|-----------------|--|--|--|
| Drug Code | Name of the Drug and Specification | Drug Type | Approx. Requirements | EPROC. CODE | | | |
| 1 | 2 | 3 | 4 | 5 | | | |
| ANTACIDS | | | | | | | |
| 1 | SUSP DRIED ALUMINIUM HYDROIXIDE GEL 200mg MAGNESIUM HYDROXIDE 250mg WITH POLYSILOXANE 20mg PER 5ml IN 170ml BOTTLE | SUSP | 2,262 | RCDRUGS001 | | | |
| 2 | SUCRALFATE 200MG/5ML OXETACAINE 10MG/5ML | SYRUP | 20 | RCDRUGS002 | | | |
| 3 | INJ ESOMEPRAZOLE 40MG | INJ | 200 | RCDRUGS003 | | | |
| 4 | INJ HYOSCINE BUTYLBROMIDE 20MG | INJ | 20 | RCDRUGS004 | | | |
| 5 | TAB HYOSCINE BUTYLBROMIDE 10MG | TABLET | 1,000 | RCDRUGS005 | | | |
| 6 | TAB LANSOPRAZOLE 15MG | TABLET | 5,000 | RCDRUGS006 | | | |
| 7 | TAB LANSOPRAZOLE JUNIOR 30MG | TABLET | 50 | RCDRUGS007 | | | |
| 8 | TAB RANITIDINE 150MG | TABLET | 37,170 | RCDRUGS008 | | | |
| 9 | INJ RANITIDINE HCL 25mg/ml 2ml AMPS | INJ | 48,815 | RCDRUGS009 | | | |
| 10 | SYRUP RANITIDINE 75MG/5ML 100ML BOTTLE | SYRUP | 100 | RCDRUGS010 | | | |
| 11 | TAB RACECADOTRIL 100MG | TABLET | 150 | RCDRUGS011 | | | |
| 12 | CAP OMEPRAZOLE 20mg | CAPS | 26,664 | RCDRUGS012 | | | |
| 13 | TAB PANTAPRAZOLE 40mg | TABLET | 79,224 | RCDRUGS013 | | | |
| 14 | INJ PANTAPRAZOLE 40mg VIAL | INJ | 14,243 | RCDRUGS014 | | | |
| | ANTHELMINTIC | ı | , | | | | |
| 15 | TAB ALBENDAZOLE 400mg | TABLET | 1,889 | RCDRUGS015 | | | |
| | BULK LAXATIVES | | , | | | | |
| 16 | TAB BISACODYL 10MG | TABLET | 250 | RCDRUGS016 | | | |
| 4= | | SUPPOSI | | | | | |
| 17 | SUPPOSITORIES BISACODYL 10MG | TORIES | 200 | RCDRUGS017 | | | |
| 18 | LIQ PARAFFIN 450ml | SOLUTIO N | 652 | RCDRUGS018 | | | |
| 19 | SYRUP MILK OF MAGNESIA WITH LIQUID PARAFFIN | SYRUP | 50 | RCDRUGS019 | | | |
| 20 | SYRUP LACTULOSE 200ml | SYRUP | 60 | RCDRUGS020 | | | |
| | ANTI CHOLINESTERASE | S | | | | | |
| 21 | INJ ATROPINE SULPHATE 0.60mg/ml I.P. AMP | INJ | 9,269 | RCDRUGS021 | | | |
| 22 | TAB DONEPEZIL 5 MG | TABLET | 1,80,000 | RCDRUGS022 | | | |
| 23 | TAB DONEPEZIL 10 MG | TABLET | 798 | RCDRUGS023 | | | |
| 24 | TAB MEMANTINE 5MG | TABLET | 300 | RCDRUGS024 | | | |
| 25 | TAB MEMANTINE 10MG | TABLET | 100 | RCDRUGS025 | | | |
| 26 | INJ GLYCOPYRRONIUM BROMIDE 0.2mg IM/IV | INJ | 17,837 | RCDRUGS026 | | | |
| 27 | TAB GLYCOPYRROLATE 1MG | TABLET | 3,000 | RCDRUGS027 | | | |
| 28 | TAB GLYCOPYRROLATE 2MG | TABLET | 1,260 | RCDRUGS028 | | | |
| 29 | TAB PYRIDOSTIGMINE 60mg | TABLET | 1,39,290 | RCDRUGS029 | | | |
| 30 | INJ NEOSTIGMINE METHYL SULPHATE 0.5MG/ML 1ML | INJ | 42,680 | RCDRUGS030 | | | |
| | CVS DRUGS, DIURETIC | S | | | | | |
| 31 | TAB ACETAZOLAMIDE 250MG | TABLET | 4,458 | RCDRUGS031 | | | |
| 32 | INJ ADENOSINE 3MG/ML 2ML AMP | INJ | 118 | RCDRUGS032 | | | |
| 33 | TAB AMIODARONE 50MG/ ML | INJ | 329 | RCDRUGS033 | | | |
| 34 | TAB AMLODIPINE BESYLATE 5MG | TABLET | 19,839 | RCDRUGS034 | | | |
| 35 | TAB ASPIRIN 75MG (ENTERIC COATED) | TABLET | 1,03,571 | RCDRUGS035 | | | |
| 36 | TAB ASPIRIN 150MG (ENTERIC COATED) | TABLET | 500 | RCDRUGS036 | | | |
| 37 | CAP ASPIRIN AND ATORVASTATIN 75MG/10MG | CAPS | 2,000 | RCDRUGS037 | | | |
| 38 | CAP ASPIRIN AND ATORVASTATIN 75MG / 20MG | CAPS | , , | RCDRUGS038 | | | |
| 39 | TAB ATENOLOL 50MG | TABLET | 720 | RCDRUGS039 | | | |
| 40 | TAB ATORVASTATIN 10MG | TABLET | 12,441 | RCDRUGS040 | | | |
| | | | . , , , , , , , , , , , , , , , , , , , | | | | |

| 41 | TAB ATORVASTATIN 40MG | TABLET | 360 | RCDRUGS041 | | | |
|---------------------|--|--------|----------|--------------|--|--|--|
| 42 | TAB CILNIDIPINE 5MG | TABLET | 402 | RCDRUGS042 | | | |
| 43 | TAB CILNIDIPINE 10MG | TABLET | 200 | RCDRUGS043 | | | |
| 44 | TAB CLONIDINE 150MCG | TABLET | 50 | RCDRUGS044 | | | |
| 45 | TAB CLOPIDOGREL 75MG | TABLET | 2,226 | RCDRUGS045 | | | |
| 46 | INJ EPHEDRINE 30MG/ML AMP. | INJ | 100 | RCDRUGS046 | | | |
| 47 | TAB ENALAPRIL MALEATE 5MG | TABLET | 1,104 | RCDRUGS047 | | | |
| 48 | INJ ESMOLOL 100MG/ 10ML | INJ | 424 | RCDRUGS048 | | | |
| 49 | TAB FENOFIBRATE 145MG | TABLET | 500 | RCDRUGS049 | | | |
| 50 | TAB FENOFIBRATE 200MG | TABLET | 700 | RCDRUGS050 | | | |
| 51 | CAP FENOFIBRATE 200MG | CAPS | 200 | RCDRUGS051 | | | |
| 52 | TAB FENOFIBRATE 67MG | TABLET | 700 | RCDRUGS052 | | | |
| 53 | CAP FENOFIBRATE 67MG | CAPS | 500 | RCDRUGS053 | | | |
| 54 | TAB FLUDROCORTISONE 100 MCG | TABLET | 1,068 | RCDRUGS054 | | | |
| 55 | INJ FRUSEMIDE 10MG/ML 2ML AMP | INJ | 4,970 | RCDRUGS055 | | | |
| 56 | TAB FRUSEMIDE 40MG | TABLET | 1,236 | RCDRUGS056 | | | |
| | GLYCERYL TRINITRATE TRANSDERMAL PATCH | | 100 | | | | |
| 57 | 5MG/24HOURS | PATCH | | RCDRUGS057 | | | |
| 58 | INJ ISOPRENALINE 2MG/ML 1ML | INJ | 50 | RCDRUGS058 | | | |
| 59 | TAB ISOSORBIDE DINITRATE 10MG | TABLET | 936 | RCDRUGS059 | | | |
| 60 | TAB ISOSORBIDE MONO NITRATE 30MG SR | TABLET | 411 | RCDRUGS060 | | | |
| 61 | INJ LABETALOL 20MG/ 4ML | INJ | 2,301 | RCDRUGS061 | | | |
| 62 | TAB LOSARTAN POTASSIUM IP 25MG | TABLET | 100 | RCDRUGS062 | | | |
| 63 | TAB LOSARTAN POTASSIUM IP 50MG | TABLET | 100 | RCDRUGS063 | | | |
| 64 | INJ MILRINONE 10MG/10ML | INJ | 379 | RCDRUGS064 | | | |
| 65 | INJ MEPHENTARAMINE 30mg / ml 10ml vial IM/IV | INJ | 875 | RCDRUGS065 | | | |
| 66 | INJ METOPROLOL 5MG/5ML | INJ | 500 | RCDRUGS066 | | | |
| 67 | TAB METOPROLOL 12.5MG | TABLET | 100 | RCDRUGS067 | | | |
| 68 | TAB METOPROLOL 25MG | TABLET | 500 | RCDRUGS068 | | | |
| 69 | TAB METOPROLOL 50MG | TABLET | 100 | RCDRUGS069 | | | |
| 70 | INJ NIMODIPINE 10mg IN 50ML VIAL IV | INJ | 501 | RCDRUGS070 | | | |
| 71 | TAB NIMODIPINE 30mg | TABLET | 26,154 | RCDRUGS071 | | | |
| 72 | INJ NITROGLYCERINE 25MG/5ML 5 ML AMP | INJ | 279 | RCDRUGS072 | | | |
| 73 | TAB ORCIPRENALINE 10MG | TABLET | 50 | RCDRUGS073 | | | |
| 74 | INJ POTASSIUM CHLORIDE 15 PERCENT W/V 10ML AMP | INJ | 20 | RCDRUGS074 | | | |
| 75 | TAB PIRACETAM 400MG | TABLET | 20 | RCDRUGS075 | | | |
| 76 | TAB PIRACETAM 800MG | TABLET | 100 | RCDRUGS076 | | | |
| 77 | INJ PIRACETAM 200MG/ML | INJ | 100 | RCDRUGS077 | | | |
| 78 | TAB PROPRANOLOL 20MG | TABLET | 30,000 | RCDRUGS078 | | | |
| 79 | TAB PROPRANOLOL 40MG | TABLET | 1,82,892 | RCDRUGS079 | | | |
| 80 | TAB PROPRANOLOL 40MG SR | TABLET | 1,000 | RCDRUGS080 | | | |
| 81 | TAB RAMIPRIL 2.5MG | TABLET | 1,140 | RCDRUGS081 | | | |
| 82 | TAB RAMIPRIL 5MG | TABLET | 500 | RCDRUGS082 | | | |
| 83 | TAB RIVAROXABAN 15MG | TABLET | 100 | RCDRUGS083 | | | |
| 84 | TAB ROSUVASTATIN 10MG | TABLET | 175 | RCDRUGS084 | | | |
| 85 | TAB ROSUVASTATIN 10MG | TABLET | 200 | RCDRUGS085 | | | |
| 86 | TAB ROSUVASTATIN 40MG | TABLET | 100 | RCDRUGS086 | | | |
| 87 | TAB ROSUVASTATIN AND ASPIRIN 10/75MG | TABLET | 2200 | RCDRUGS087 | | | |
| 88 | TAB ROSUVASTATIN AND ASPIRIN 20/75MG | TABLET | 1000 | RCDRUGS088 | | | |
| 89 | TAB TELMISARTAN 40MG | TABLET | 726 | RCDRUGS089 | | | |
| 90 | TAB TOLVAPTAN 15MG | TABLET | 300 | RCDRUGS090 | | | |
| 91 | INJ VASOPRESSIN 20IU/ml 1ml | INJ | 1,141 | RCDRUGS090 | | | |
| ADRENERGIC AGONISTS | | | | | | | |
| 92 | INJ ADRENALINE TARTRATE 0.1% W/V 1ml AMP | INJ | 7,545 | RCDRUGS092 | | | |
| 93 | INJ DOBUTAMINE 250mg/5ml-5ml AMP | INJ | 1,060 | RCDRUGS092 | | | |
| 93 | 1110 DODO I AMINIL 2001119/01111-01111 AMI | IIIJ | 1,000 | 170017003033 | | | |

| 94 | INJ DOPAMINE USP 200MG/5ml AMP | INJ | 2,988 | RCDRUGS094 |
|-----|---|-------------------|--------|------------|
| 95 | INJ NORADRENALINE 4MG/2ML 2 ML AMP | INJ | 14,419 | RCDRUGS095 |
| | ANTICOAGULANTS | | | |
| 96 | INJ ALTEPLASE 20MG | INJ | 10 | RCDRUGS096 |
| 97 | INJ ALTEPLASE 50MG | INJ | 30 | RCDRUGS097 |
| 98 | INJ CITICHOLINE 250MG/ML | INJ | 50 | RCDRUGS098 |
| 99 | TAB CITICHOLINE 500MG | TABLET | 70 | RCDRUGS099 |
| 100 | INJ EDARAVONE 1.5GM/ML 20ML VIAL/ AMPULE | INJ | 1,628 | RCDRUGS100 |
| 101 | INJ ENOXAPARIN 40MG/0.4ML SUBCUTANEOUS PREFILLED SYRINGE | INJ | 500 | RCDRUGS101 |
| 102 | INJ ENOXAPARIN 60mg/0.6ML | INJ | 1,000 | RCDRUGS102 |
| 103 | INJ DELTAHEPARIN SODIUM 10,000 UNITS/ 10ML | INJ | 25 | RCDRUGS103 |
| 104 | INJ HEPARIN IP 5000IU/ML 5ML VIAL IV / IM / SC | INJ | 7,807 | RCDRUGS104 |
| 105 | OINTMENT HEPARIN SODIUM IP 50IU/GM 20gm TUBE | OINT | 1,015 | RCDRUGS105 |
| 106 | LOW MOLECULAR WEIGHT HEPARIN 10,000 IU/ml 10ml VIAL (MULTI DOSE) | INJ | 40 | RCDRUGS106 |
| 107 | TAB NICOUMALONE 1MG | TABLET | 350 | RCDRUGS107 |
| 108 | INJ TENECTEPLASE 20MG | INJ | 3 | RCDRUGS108 |
| 109 | INJ TRANEXAMIC ACID 500MG/5ML | INJ | 1,755 | RCDRUGS109 |
| 110 | INJ UROKINASE 5 LAKH IU | INJ | 20 | RCDRUGS110 |
| | ANALGESIC AND ANTIPYRI | | | |
| 111 | TAB ACECLOFENAC 100MG | TABLET | 5,000 | RCDRUGS111 |
| 112 | TAB DICLOFENAC SODIUM 50mg (ENTERIC COATED) | TABLET | 44,778 | RCDRUGS112 |
| 113 | INJ DICLOFENAC 75MG I.V. ONLY | INJ | 39,225 | RCDRUGS113 |
| 114 | INJ DICLOFENAC 75MG IM / IV | INJ | 2,000 | RCDRUGS114 |
| 115 | GEL DICLOFENAC SODIUM GEL 1% W/V 30GMS/TUBE | GEL | 500 | RCDRUGS115 |
| 116 | PATCH DICLOFENAC SODIUM 100MG | PATCH | 20 | RCDRUGS116 |
| 117 | PATCH DICLOFENAC SODIUM 200MG | PATCH | 20 | RCDRUGS117 |
| 118 | TAB DICYCLOMINE 20MG + PARACCETAMOL 500MG | TABLET | 3,000 | RCDRUGS118 |
| 119 | TAB KETOROLAC 10 MG | TABLET | 1,000 | RCDRUGS119 |
| 120 | TAB NAPROXEN 500MG + DOMPERIDONE 10MG | TABLET | 2,000 | RCDRUGS120 |
| 121 | TAB PARACETAMOL 500MG | TABLET | 62,541 | RCDRUGS121 |
| 122 | TAB PARACETAMOL 650MG | TABLET | 40,000 | RCDRUGS122 |
| 123 | INJ PARACETAMOL 75mg/ml IM AMPOULE | INJ | 1,451 | RCDRUGS123 |
| 124 | INJ PARACETAMOL 150mg I.V. ONLY | INJ | 200 | RCDRUGS124 |
| 125 | INJ PARACETAMOL I.V. 1gm/100ML | INJ | 25,342 | RCDRUGS125 |
| 126 | SYRUP PARACETAMOL 125mg/5ml 60ml BOTTLE | SYRUP | 279 | RCDRUGS126 |
| 127 | PARACETAMOL 80 MG | SUPPOSI TORIES | 267 | RCDRUGS127 |
| 128 | PARACETAMOL 125 MG | SUPPOSI TORIES | 200 | RCDRUGS128 |
| 129 | PARACETAMOL 250 MG | SUPPOSI TORIES | 50 | RCDRUGS129 |
| 130 | TAB TRAMADOL 50MG | TABLET | 2,000 | RCDRUGS130 |
| 131 | TAB TRYPSIN CHYMOTRYPSIN | TABLET | 400 | RCDRUGS131 |
| | ANTI EMETICS | | | |
| 132 | TAB DOMPERIDONE 10MG | TABLET | 4,107 | RCDRUGS132 |
| 133 | INJ METACLOPROMIDE 5MG/ML 2ML | INJ | 500 | RCDRUGS133 |
| 134 | TAB ONDANSETRON 4MG | TABLET | 120 | RCDRUGS134 |
| 135 | INJ ONDANSETRON 2MG/ML 2ML AMP | INJ | 44,513 | RCDRUGS135 |
| 136 | SYRUP ONDANSETRON 2MG / 5 ML | SYRUP | 100 | RCDRUGS136 |
| 137 | TAB PROMETHAZINE 25MG | TABLET | 2,883 | RCDRUGS137 |

| 138 | INJ PROMETHAZINE 25MG/ML 2ML | INJ | 4,817 | RCDRUGS138 |
|-----|---|------------------|---------------|------------|
| | PSYCHOTROPICS | | | |
| | TAB AMISULPRIDE 200MG | TABLET | 7,386 | RCDRUGS139 |
| | TAB AMISULPRIDE 400MG | TABLET | 4,000 | RCDRUGS140 |
| | TAB AMITRIPTYLINE 10MG | TABLET | 50,000 | RCDRUGS141 |
| | TAB AMITRIPTYLINE 25MG | TABLET | 72,000 | RCDRUGS142 |
| | TAB AMITRIPTYLINE 75MG | TABLET | 4,27,116 | RCDRUGS143 |
| | TAB ARIPIPRAZOLE 5MG | TABLET | 60,000 | RCDRUGS144 |
| | TAB ARIPIPRAZOLE 10MG | TABLET | 72,000 | RCDRUGS145 |
| | TAB ARIPIPRAZOLE 20MG | TABLET | 50,000 | RCDRUGS146 |
| | TAB ATOMOXETINE 10 MG | TABLET | 50,000 | RCDRUGS147 |
| | TAB ATOMOXETINE 18 MG | TABLET | 50,000 | RCDRUGS148 |
| | TAB ATOMOXETINE 25 MG | TABLET | 500 | RCDRUGS149 |
| | TAB CHLORPROMAZINE HCL IP 50MG | TABLET | 97,440 | RCDRUGS150 |
| | TAB CHLORPROMAZINE HCL IP 100MG | TABLET | 6,27,306 | RCDRUGS151 |
| | TAB CHLORPROMAZINE HCL IP 200MG | TABLET | 2,02,008 | RCDRUGS152 |
| | TAB CLOMIPRAMINE 25MG | TABLET | 762 | RCDRUGS153 |
| | TAB CLOMIPRAMINE 50MG | TABLET | 1,542 | RCDRUGS154 |
| | TAB CLOMIPRAMINE 75MG | TABLET | 1,000 | RCDRUGS155 |
| | TAB CLONAZEPAM 0.25 MG | TABLET | 4,944 | RCDRUGS156 |
| | TAB CLONAZEPAM 0.50 MG | TABLET | 32,634 | RCDRUGS157 |
| | TAB CLONAZEPAM 1 MG | TABLET | 1,00,000 | RCDRUGS158 |
| | TAB CLONAZEPAM 2 MG | TABLET | 1,95,294 | RCDRUGS159 |
| | TAB CLONIDINE HCL 100 MCG | TABLET | 1,00,000 | RCDRUGS160 |
| | TAB CLONIDINE HCL 100 UG | TABLET | 80,000 | RCDRUGS161 |
| | INJ CLONIDINE 100 MCG | INJ | 100 | RCDRUGS162 |
| | TAB CLOZAPINE 100MG | TABLET | 5,55,066 | RCDRUGS163 |
| | TAB CLOZAPINE 25MG | TABLET | 8,346 | RCDRUGS164 |
| | TAB DIAZEPAM 5 MG | TABLET | 3,95,370 | RCDRUGS165 |
| | TAB DIAZEPAM 10 MG | TABLET | 3,00,000 | RCDRUGS166 |
| | INJ DIAZEPAM IM/IV 10 MG 2ML AMP | INJ | 2,936 | RCDRUGS167 |
| | TAB DESVENLAFAXINE 50MG | TABLET | 45,000 | RCDRUGS168 |
| | TAB DESVENLAFAXINE 100MG | TABLET | 45,000 | RCDRUGS169 |
| | TAB MELATONIN 3MG | TABLET | 300 | RCDRUGS170 |
| | TAB ESCITALOPRAM 5 MG | TABLET | 10,000 | RCDRUGS171 |
| | TAB ESCITALOPRAM 10 MG | TABLET | 85,000 | RCDRUGS172 |
| | TAB ESCITALOPRAM 20 MG | TABLET | 10,000 | RCDRUGS173 |
| 174 | TAB FLUOXETINE 10MG | TABLET | 10,000 | RCDRUGS174 |
| 175 | TAB FLUOXETINE 20MG | TABLET / CAPS | 15,80,36 4 | RCDRUGS175 |
| 176 | SYRUP FLUOXETINE 20MG/5ML | SYRUP | 200 | RCDRUGS176 |
| | TAB FLUPENTHIXOL 3MG | TABLET | 400 | RCDRUGS177 |
| | INJ FLUPENTHIXOL (DEPOT) 20MG | INJ | 14,000 | RCDRUGS178 |
| 179 | INJ FLUPHENAZINE DECANOATE BP 25MG/ML 1ML AMP | INJ | 28,231 | RCDRUGS179 |
| | TAB GABAPENTINE 100MG | TABLET | 2,880 | RCDRUGS180 |
| | TAB GABAPENTINE 150MG | TABLET | 1,500 | RCDRUGS181 |
| | TAB GABAPENTINE 300MG | TABLET | 1,998 | RCDRUGS182 |
| | TAB HALOPERIDOL 0.5MG | TABLET | 250 | RCDRUGS183 |
| | TAB HALOPERIDOL 1.5MG | TABLET | 500 | RCDRUGS184 |
| | TAB HALOPERIDOL 5MG | TABLET | 24,132 | RCDRUGS185 |
| 186 | INJ HALOPERIDOL 5MG/ML 1ML AMP IM/IV | INJ | 14,829 | RCDRUGS186 |
| 187 | INJ HALOPERIDOL L.A. 50MG | INJ | 100 | RCDRUGS187 |
| 188 | TAB ILOPERIDONE 4MG | TABLET | 200 | RCDRUGS188 |
| 189 | TAB IMIPRAMINE 25MG | TABLET | 54,156 | RCDRUGS189 |
| 190 | TAB IMIPRAMINE 75MG | TABLET | 1,04,430 | RCDRUGS190 |

| 192 | 191 | TAB LAMOTRIGINE 100MG | TABLET | 500 | RCDRUGS191 |
|--|-----|---------------------------------------|---------|----------|------------|
| 193 TAB LORAZEPAM 2MG | 192 | TAB LITHIUM CARBONATE 300MG | TABLET | | RCDRUGS192 |
| 194 N.J. LORAZEPAM ZMIGMIL ZMIL AMP | 193 | TAR LORAZEPAM 2MG | TARI ET | _ | RCDRUGS193 |
| 195 TAB LURASIDONE 40MG | | | | • | |
| TAB METHYLPHENIDATE (IMMEDIATE RELEASE) 5 TABLET 50,000 RCDRUGS196 MG | | | | | |
| 197 | | | | | |
| 198 | 196 | MG | TABLET | 50,000 | RCDRUGS196 |
| 199 | 197 | 10 MG | TABLET | 50,000 | RCDRUGS197 |
| 199 20 MG | 198 | 18 MG | TABLET | 20,000 | RCDRUGS198 |
| TABLET | 199 | | TABLET | 40,000 | RCDRUGS199 |
| TABLET | 200 | TAB MIRTAZAPINE 15MG | TABLET | 500 | RCDRUGS200 |
| TAB OLANZAPINE 20MG | 201 | TAB MIRTAZAPINE 30MG | TABLET | 100 | RCDRUGS201 |
| TAB OLANZAPINE 5MG | 202 | TAB OLANZAPINE 10MG | TABLET | 11,613 | RCDRUGS202 |
| 205 INJ OLANZAPINE LA 210 MG | 203 | TAB OLANZAPINE 20MG | TABLET | 60 | RCDRUGS203 |
| 206 | 204 | TAB OLANZAPINE 5MG | TABLET | 13,494 | RCDRUGS204 |
| 206 | 205 | INJ OLANZAPINE LA 210 MG | INJ | 50 | RCDRUGS205 |
| 207 | | INJ OLANZAPINE LA 300MG | | 50 | |
| TAB QUETIAPINE 25 MG | | | | | RCDRUGS207 |
| 209 TAB QUETIAPINE 100 MG | | | | | |
| TAB QUETIAPINE 200 MG | | | | | l . |
| TAB QUETIAPINE 300 MG | | | | | |
| TAB RISPERIDONE 0.5 MG (SCORED TABLET) | | | | | |
| 213 TAB RISPERIDONE 1 MG (SCORED TABLET) TABLET 50,000 RCDRUGS213 | | | | | |
| TABLET | | | | | |
| TAB | | | | • | |
| TABLET | | | | | |
| TABLET | | | | | |
| 218 | | | | 18,12,76 | |
| 219 | | | | _ | |
| 220 | | | | | |
| 221 SYRUP RISPERIDONE 1 MG /ML | | | | | |
| 222 TAB SERTRALINE 25MG TABLET 324 RCDRUGS222 223 TAB SERTRALINE 50MG TABLET 324 RCDRUGS223 224 TAB SERTRALINE 100MG TABLET 50 RCDRUGS224 225 SYRUP TRICLOFOS ORAL SOLUTION 500MG/5ML 30ml SYRUP 50 RCDRUGS225 226 TAB TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS226 227 TBA TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS227 228 CAP VENLAFAXINE 75MG CAPS 1,510 RCDRUGS228 229 CAP VENLAFAXINE 150MG CAPS 50 RCDRUGS229 230 INJ ZUCLOPENTHIXOL ACETATE (ACUPHASE) 50MG/ML 1ML INJ 7,020 RCDRUGS230 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) 200MG/ML 1ML INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | | | | | |
| 223 TAB SERTRALINE 50MG TABLET 324 RCDRUGS223 224 TAB SERTRALINE 100MG TABLET 50 RCDRUGS224 225 SYRUP TRICLOFOS ORAL SOLUTION 500MG/5ML 30ml SYRUP 50 RCDRUGS225 226 TAB TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS226 227 TBA TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS227 228 CAP VENLAFAXINE 75MG CAPS 1,510 RCDRUGS228 229 CAP VENLAFAXINE 150MG CAPS 50 RCDRUGS229 230 INJ ZUCLOPENTHIXOL ACETATE (ACUPHASE) 50MG/ML 1ML INJ 7,020 RCDRUGS230 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) 200MG/ML 1ML INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | | | | | |
| 224 TAB SERTRALINE 100MG TABLET 50 RCDRUGS224 225 SYRUP TRICLOFOS ORAL SOLUTION 500MG/5ML 30ml SYRUP 50 RCDRUGS225 226 TAB TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS226 227 TBA TRIHEXYPHENIDYL HCL 2MG TABLET 40,97,65 8 RCDRUGS227 228 CAP VENLAFAXINE 75MG CAPS 1,510 RCDRUGS228 229 CAP VENLAFAXINE 150MG CAPS 50 RCDRUGS229 230 INJ ZUCLOPENTHIXOL ACETATE (ACUPHASE) 50MG/ML 1ML INJ 7,020 RCDRUGS230 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) 200MG/ML 1ML INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS TABLET 1,56,530 RCDRUGS232 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS233 233 TAB BENFOTHIAMINE 100MG TABLET 1,00 RCDRUGS233 | | | TABLET | 324 | |
| 225 SYRUP TRICLOFOS ORAL SOLUTION 500MG/5ML SYRUP 50 RCDRUGS225 | 223 | | TABLET | 324 | |
| 225 30ml SYRUP 50 RCDRUGS225 | 224 | TAB SERTRALINE 100MG | TABLET | 50 | RCDRUGS224 |
| 226 TAB TRIHEXTPHENIDTL HCL 2MG | 225 | | SYRUP | 50 | RCDRUGS225 |
| 227 TBA TRIHEXTPHENIDTL HCL 2MG | 226 | TAB TRIHEXYPHENIDYL HCL 2MG | TABLET | | RCDRUGS226 |
| 229 CAP VENLAFAXINE 150MG CAPS 50 RCDRUGS229 230 INJ ZUCLOPENTHIXOL ACETATE (ACUPHASE) 50MG/ML 1ML INJ 7,020 RCDRUGS230 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) 200MG/ML 1ML INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | 227 | TBA TRIHEXYPHENIDYL HCL 2MG | TABLET | | RCDRUGS227 |
| 229 CAP VENLAFAXINE 150MG CAPS 50 RCDRUGS229 230 INJ ZUCLOPENTHIXOL ACETATE (ACUPHASE) 50MG/ML 1ML INJ 7,020 RCDRUGS230 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) 200MG/ML 1ML INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | 228 | CAP VENLAFAXINE 75MG | CAPS | 1,510 | RCDRUGS228 |
| 230 50MG/ML 1ML INJ 7,020 RCDRUGS230 | 229 | CAP VENLAFAXINE 150MG | CAPS | - | RCDRUGS229 |
| 231 INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) INJ 48 RCDRUGS231 DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | 230 | · · · · · · · · · · · · · · · · · · · | INJ | 7,020 | RCDRUGS230 |
| DE- ADDICTIVE DRUGS 232 TAB ACAMPROSATE 333MG TABLET 1,56,530 RCDRUGS232 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | 231 | INJ ZUCLOPENTHIXOL DECANOATE (DEPOT) | INJ | 48 | RCDRUGS231 |
| 232TAB ACAMPROSATE 333MGTABLET1,56,530RCDRUGS232233TAB BENFOTHIAMINE 100MGTABLET100RCDRUGS233 | | | 3 | ı | 1 |
| 233 TAB BENFOTHIAMINE 100MG TABLET 100 RCDRUGS233 | 232 | | | 1,56.530 | RCDRUGS232 |
| | | | | | |
| | 234 | INJ BUPRENORPHINE 0.3 MG | INJ | | RCDRUGS234 |

| 235 | TAB BUPRENORPHINE 0.4 MG | TABLET | 34,800 | RCDRUGS235 |
|-----|--|--------|---------------|------------|
| 236 | TAB BUPRENORPHINE 2 MG | TABLET | 20,400 | RCDRUGS236 |
| 237 | TAB BUPRENORPHINE 2MG WITH NALOXONE 0.5MG | TABLET | 2,10,000 | RCDRUGS237 |
| 238 | TAB BUPROPION HYDROCHLORIDE EXTENDED RELEASE U.S.P150MG | TABLET | 27,036 | RCDRUGS238 |
| 239 | TAB NALTREXONE 50MG | TABLET | 1,25,760 | RCDRUGS239 |
| 240 | INJ NALOXONE 0.4MG | INJ | 20 | RCDRUGS240 |
| 241 | NICOTIN GUM 2MG | GUM | 3,97,562 | RCDRUGS241 |
| 242 | NICOTIN TRANSDERMAL PATCH 14MG/24hours | PATCH | 500 | RCDRUGS242 |
| 243 | NICOTIN TRANSDERMAL PATCH 21MG/24hours | PATCH | 2,000 | RCDRUGS243 |
| 244 | TAB TOPIRAMATE 50MG | TABLET | 80,496 | RCDRUGS244 |
| 245 | MULTI DRUG DETECTION KIT | KIT | 00,400 | RCDRUGS245 |
| 246 | CANNABINOID DETECTION KIT | KIT | | RCDRUGS246 |
| 240 | ANTI PARKINSONISM | KH | | NODNOG5240 |
| 247 | CAP AMANTADINE 100MG | TABLET | 700 | RCDRUGS247 |
| 248 | TAB ENTACAPONE 200MG | TABLET | 3000 | RCDRUGS248 |
| 249 | TAB LEVODOPA 100MG + CARBIDOPA 10MG | TABLET | 2,65,782 | RCDRUGS249 |
| | TAB LEVODOPA 100MG + CARBIDOPA 10MG TAB LEVODOPA 100MG + CARBIDOPA 25MG | | | |
| 250 | | TABLET | 14,000 | RCDRUGS250 |
| 251 | TAB PRAMIPEXOLE 0.25MG | TABLET | 50 | RCDRUGS251 |
| 252 | TAB PRAMIPEXOLE 0.5MG | TABLET | 50 | RCDRUGS252 |
| 253 | TAB PRAMIPEXOLE 1MG | TABLET | 50 | RCDRUGS253 |
| 254 | TAB ROPINROLE 0.5MG | TABLET | 50 | RCDRUGS254 |
| 255 | TAB ROPINROLE 1MG | TABLET | 50 | RCDRUGS255 |
| 256 | TAB TETRABENAZINE 25MG | TABLET | 1,920 | RCDRUGS256 |
| | ANTI EPILEPTICS | | | |
| 257 | TAB BRIVARACETAM 50MG | TABLET | 15,000 | RCDRUGS257 |
| 258 | TAB CARBAMAZEPINE BP 200MG | TABLET | 18,66,99 0 | RCDRUGS258 |
| 259 | SYRUP CARBAMAZEPINE BP 200MG | SYRUP | 200 | RCDRUGS259 |
| 260 | TAB CLOBAZAM 5MG | TABLET | 2,045 | RCDRUGS260 |
| 261 | TAB CLOBAZAM 10MG | TABLET | 5,190 | RCDRUGS261 |
| 262 | TAB DIPHENYLHYDANTION SODIUM IP 50MG | TABLET | 1,00,000 | RCDRUGS262 |
| 263 | TAB DIPHENYLHYDANTOIN SODIUM IP 100MG | TABLET | 7,17,804 | RCDRUGS263 |
| 264 | INJ DIPHENYLHYDANTOIN SODIUM IP 50MG/ML IV/IM 2ML AMP | INJ | 1,25,836 | RCDRUGS264 |
| 265 | SYRUP DIPHENYLHYDANTOIN SODIUM SYRUP | SYRUP | 500 | RCDRUGS265 |
| 266 | INJ FOSPHENYTOIN 75MG /ml 10ml vial | INJ | 200 | RCDRUGS266 |
| 267 | TAB LACOSAMIDE 50MG | TABLET | 10,000 | RCDRUGS267 |
| 268 | TAB LACOSAMIDE 100MG | TABLET | 5,000 | RCDRUGS268 |
| 269 | INJ LACOSAMIDE 10MG/ML | INJ | 500 | RCDRUGS269 |
| 270 | INJ LACOSAMIDE 200MG/20ML | INJ | 500 | RCDRUGS270 |
| 271 | TAB LAMOTRIGINE 25MG | TABLET | 2,000 | RCDRUGS271 |
| 272 | TAB LAMOTRIGINE 50MG | TABLET | 600 | RCDRUGS272 |
| 273 | TAB LAMOTRIGINE 100MG | TABLET | 1,000 | RCDRUGS272 |
| 274 | TAB LEVETIRACETAM 250MG | TABLET | 300 | RCDRUGS274 |
| 275 | TAB LEVETIRACETAM 250MG | TABLET | 16,872 | RCDRUGS274 |
| 276 | INJ LEVETIRACETAM 500MG | INJ | 20,343 | RCDRUGS276 |
| 276 | | | • | |
| | SYRUP LEVETIRACETAM 100MG/ML 100ML | SYRUP | 1,200 | RCDRUGS277 |
| 278 | TAB PHENOBARBITONE 30MG | TABLET | 46,188 | RCDRUGS278 |
| 279 | TAB PHENOBARBITONE 60MG | TABLET | 3,44,778 | RCDRUGS279 |
| 280 | INJ PHENOBARBITONE NFI 200MG/ML 1ML AMP. | INJ | 110 | RCDRUGS280 |
| 281 | TAB PREGABALIN 75MG | TABLET | 1,890 | RCDRUGS281 |
| 282 | TAB VALPROATE SODIUM BP 200MG | TABLET | 6,52,311 | RCDRUGS282 |
| 283 | TAB VALPROATE SODIUM BP 500MG | TABLET | 14,26,44 9 | RCDRUGS283 |

| | INJ VALPROATE SODIUM 500MG I.V. ONLY | INJ | 5,460 | RCDRUGS284 |
|----------|---|----------|--------|-------------|
| 285 | SYRUP VALPROATE SODIUM 200MG/5ML | SYRUP | 1,200 | RCDRUGS285 |
| | ANTIVERTIGO | | • | ' |
| 286 | TAB BETAHISTINE I.P. 8MG | TABLET | 800 | RCDRUGS286 |
| 287 | TAB BETAHISTINE I.P. 16MG | TABLET | 400 | RCDRUGS287 |
| 288 | TAB FLUNARIZINE 5MG | TABLET | 500 | RCDRUGS288 |
| 289 | TAB FLUNARIZINE 10MG | TABLET | 500 | RCDRUGS289 |
| | NARCOTIC DRUGS | | | |
| 290 | INJ PAPAVERINE 30mg/ml 2ml AMP | INJ | 192 | RCDRUGS290 |
| | INJ MORPHINE 10MG/ML | INJ | 1,500 | RCDRUGS291 |
| | INJ MORPHINE 15MG/ML | INJ | 5,396 | RCDRUGS292 |
| | INJ FENTANYL CITRATE 50mcg 2ML AMP | INJ | 13,940 | RCDRUGS293 |
| | PATCH FENTANYL TRANSDERMAL PATCH 25 | | • | |
| 744 | mcg/h PATCH | PATCH | 200 | RCDRUGS294 |
| | PATCH FENTANYL TRANSDERMAL PATCH 50 | | | |
| 745 | mcg/h PATCH | PATCH | 200 | RCDRUGS295 |
| | INJ TRAMADOL 50 MG/ML-1ml amp | INJ | 1,187 | RCDRUGS296 |
| | INJ TRAMADOL 50 MG/ML-2ml amp | INJ | 50 | RCDRUGS297 |
| | INJ TRAMADOL 100 MG/ML | INJ | 50 | RCDRUGS298 |
| 230 | ANAESTHETICS - GENER | _ | 50 | KCDKUG3230 |
| 200 | | | 404 | DODDIIOCOOO |
| | ***LIQ ISOFLURANE 250ML | LIQ | 104 | RCDRUGS299 |
| < 1 11 1 | ***LIQ SEVOFLURANE (LIQUID ANAESTHETIC) | LIQ | 1,178 | RCDRUGS300 |
| 1 | 250ML | | | |
| 3117 | ***LIQ DESFLURANE (LIQUID ANAESTHETIC) | LIQ | 488 | RCDRUGS301 |
| | 250ML | - | | |
| | ANAESTHETIC ETHER IP 500ML | LIQ | 859 | RCDRUGS302 |
| | INJ DEXMEDETOMIDINE 100MCG/1ML | INJ | 2,401 | RCDRUGS303 |
| | INJ ETOMIDATE 2 MG/ML, 10ML VIAL | INJ | 120 | RCDRUGS304 |
| | INJ KETAMINE 50MG /ML 5MLVIAL | INJ | 669 | RCDRUGS305 |
| | INJ MIDAZOLAM 1MG/ML 5ML VIAL | INJ | 6,560 | RCDRUGS306 |
| 307 | MIDAZOLAM 0.5MG NASAL SPRAY | SPRAY | 250 | RCDRUGS307 |
| 308 | INJ PENTAZOCINE 30MG | INJ | 50 | RCDRUGS308 |
| 309 | INJ PROPOFOL 10MG/ML 20ML VIAL | INJ | 11,254 | RCDRUGS309 |
| 310 | INJ PROPOFOL 1% MCT-LCT 20ML VIAL | INJ | 2,500 | RCDRUGS310 |
| 311 | INJ PROPOFOL 1% MCT-LCT 50ML VIAL | INJ | 2,500 | RCDRUGS311 |
| 312 | INJ PROPOFOL 2% EMULSION 50ML VIAL | INJ | 500 | RCDRUGS312 |
| 313 | INJ THIOPENTONE SODIUM IP 500MG IV | INJ | 7,439 | RCDRUGS313 |
| 314 | TRICLOFOS ORAL SOLUTION 30ML | LIQ | 50 | RCDRUGS314 |
| _ | LOCAL ANAESTHETICS | · | | |
| 315 | INJ BUPIVACAINE 0.5% 20ML VIAL | INJ | 2,133 | RCDRUGS315 |
| | INJ ROPIVACAINE 0.75% 30ML VIAL | INJ | 200 | RCDRUGS316 |
| | INJ LIDOCAINE 2% 30ML VIAL | INJ | 1,642 | RCDRUGS317 |
| | INJ LIDOCAINE 2% WITH ADRENALINE 30ML | | • | |
| | VIAL(1:2,00,000) | INJ | 3,780 | RCDRUGS318 |
| | INJ LIDOCAINE HCL 21.3MG/ML 50ML VIAL (WITH | | | |
| | OUT PRESERVATIVE) | INJ | 706 | RCDRUGS319 |
| | LIDOCAINE 25MG + PRILOCAINE 25MG PER GRAM | | | |
| 3711 | (LOCAL ANAESTHETIC CREAM) 5GM | CREAM | 100 | RCDRUGS320 |
| | , | OINT | 2.066 | DCDDIIC6334 |
| | OINT LIDOCAINE 2% JELLY 30GM | OINT | 2,966 | RCDRUGS321 |
| | LIDOCAINE 10% SPRAY | BOTTLE | 50 | RCDRUGS322 |
| | LIDOCAINE 4% TOPICAL 30ML | SOLUTION | 53 | RCDRUGS323 |
| | LIDOCAINE 5% PATCH | PATCH | 100 | RCDRUGS324 |
| -2-16 | VEGETABLE BASED LUBRICATING JELLY/ | OINT | 730 | RCDRUGS325 |
| - | LUBRICATING GEL | | - * | |
| 000 | SKELETAL MUSCLE RELAX | | | DODDUGGGG |
| 326 | INJ ATRACURIUM BESYLATE 10MG/ML 5ML AMP | INJ | 2,113 | RCDRUGS326 |

| | | | 15 21 76 | |
|---|--|--------|---------------|-----------------|
| 327 | TAB BACLOFEN 10MG | TABLET | 15,31,76 4 | RCDRUGS327 |
| 328 | SYRUP BACLOFEN 5MG/5ML 100ML | SYRUP | 1,200 | RCDRUGS328 |
| 329 | BOTULINIUM TOXOID 500IU | INJ | 13 | RCDRUGS329 |
| 330 | BOTULINIUM TOXOID 200IU | INJ | 13 | RCDRUGS330 |
| 331 | INJ CISATRACURIUM 10 MG / 5 ML | INJ | 78 | RCDRUGS331 |
| 332 | INJ ROCURONIUM 50 MG/5ML | INJ | 3,127 | RCDRUGS332 |
| 333 | INJ SUGGAMADEX 200MG | INJ | 100 | RCDRUGS333 |
| 334 | INJ SUGGAMADEX 500MG | INJ | 100 | RCDRUGS334 |
| 335 | INJ SUCCINYL CHOLINE NFI 50MG/ML 10ML VIAL | INJ | 774 | RCDRUGS335 |
| 336 | INJ VECURONIUM 10MG VIAL | INJ | 8,833 | RCDRUGS336 |
| | IMMAGING DRUGS | | | |
| | MACROCYCLIC GADOLINIUM CONTRAST FOR MRI | | | |
| 337 | 0.5mmol/ml 20ML VIAL | INJ | 6,120 | RCDRUGS337 |
| | MACROCYCLIC GADOLINIUM CONTRAST FOR MRI | | | |
| 338 | 1MMOL/ML, 10ML VIAL | INJ | 768 | RCDRUGS338 |
| | NON-IONIC IODINATED CONTRAST: DIMER: IODINE | | | |
| 339 | CONCENTRATION 320/270MG/ML – 100ML BOTTLE | INJ | 0 | RCDRUGS339 |
| | NON-IONIC IODINATED CONTRAST: MONOMER: | | | |
| 340 | IODINE CONCENTRATION 300MG/ML – 100ML | INJ | 9,360 | RCDRUGS340 |
| | BOTTLE | | 0,000 | I TO DITTO O TO |
| 341 | INDOCYANIN GREEN 25MG | INJ | 237 | RCDRUGS341 |
| 342 | N BUTYL CYANOARYLATE | INJ | 0 | RCDRUGS342 |
| | SODIUM TETRADECYL SULPHATE 2ML 1% | | | |
| 343 | (10MG/2ML) | INJ | 0 | RCDRUGS343 |
| 344 | TIROFIBAN HCL 5mg 100ml | INJ | 0 | RCDRUGS344 |
| • | EYE/EAR, NASAL DROP | | | I KODIKO GOGII |
| 345 | CARBOXY METHYL CELLULOSE I.P. 0.5% W/V | DROP | 50 | RCDRUGS345 |
| 346 | CIPROFLOXACIN EYE DROPS 0.3% W/V | DROP | 500 | RCDRUGS346 |
| | CIPROFLOXACIN EYE OINTMENT 0.3% W/W | | | |
| 347 | 5GRAMS TUBE | OINT | 500 | RCDRUGS347 |
| 348 | HYDROXY PROPYLMETHYL CELLULOSE (2% W/W) | OINT | 300 | RCDRUGS348 |
| 349 | MOXIFLOXACIN 0.5% EYE DROPS | DROP | 300 | RCDRUGS349 |
| | OXYMETAZOLINE NASAL SPRAY 0.05% W/V 10ML | | | |
| 350 | (PEDIATRIC) | DROP | 300 | RCDRUGS350 |
| | OXYMETAZOLINE NASAL SPRAY 0.1% W/V 10ML | | | |
| 351 | (ADULT) | DROP | 300 | RCDRUGS351 |
| | SODIUM CARBOXY METHYL CELLULOSE 1% W / V | | | |
| 352 | DROPS | DROP | 300 | RCDRUGS352 |
| | STEROIDS | | 1 | |
| 353 | INJ CORTICOTROPHIN 40 UNITS/ML U.S.P. | INJ | 200 | RCDRUGS353 |
| 354 | TAB DEXAMETHASONE 2MG | TABLET | 10,000 | RCDRUGS354 |
| 355 | TAB DEXAMETHASONE 4MG | TABLET | 10,000 | RCDRUGS355 |
| | INJ DEXAMETHASONE SODIUM PHOSPHATE | | | |
| 356 | 4MG/ML 2ML VIAL | INJ | 23,483 | RCDRUGS356 |
| | INJ HYDROCORTISONE SODIUM SUCCINATE INJ | | | |
| 357 | 100MG VIAL B.P. | INJ | 10,364 | RCDRUGS357 |
| | INJ METHYL PREDNISOLONE SODIUM SUCCINATE | | | |
| 358 | 500MG | INJ | | RCDRUGS358 |
| | INJ METHYL PREDNISOLONE SODIUM SUCCINATE | | | |
| 359 | 125MG | INJ | | RCDRUGS359 |
| | INJ METHYL PREDNISOLONE ACETATE USP | | | |
| 360 | 40MG/ML 5ML VIAL | INJ | 50 | RCDRUGS360 |
| 361 | TAB PREDNISOLONE 5MG | TABLET | 2,10,120 | RCDRUGS361 |
| 362 | TAB PREDNISOLONE 10MG | TABLET | 50,000 | RCDRUGS362 |
| 363 | TAB PREDNISOLONE 20MG | TABLET | 10,000 | RCDRUGS363 |
| 364 | TAB PREDNISOLONE 40MG | TABLET | 10,000 | RCDRUGS364 |
| JU4 | I AD I INDIVIOUS TO THE TOTAL TO THE T | IADLEI | 10,000 | 11001003304 |

| 365 | TAB PYRIMETHAMINE 25MG | TABLET | 20,000 | RCDRUGS365 |
|-----|---|-----------|---|------------|
| | THYROID DRUGS | | , | |
| 366 | TAB THYROXIN SODIUM 0.025MG | TABLET | 3,450 | RCDRUGS366 |
| 367 | TAB THYROXIN SODIUM 0.05MG | TABLET | 3,804 | RCDRUGS367 |
| 368 | TAB THYROXIN SODIUM 0.1MG | TABLET | 3,120 | RCDRUGS368 |
| | ANTI DIABETIC DRUGS | | , | 1 |
| 369 | TAB GLIBENCLAMIDE 5MG | TABLET | 500 | RCDRUGS369 |
| 370 | TAB GLIBENCLAMIDE 5MG WITH METFORMIN | TABLET | 500 | RCDRUGS370 |
| | 500MG | | | |
| 371 | TAB GLIMEPIRIDE 1MG | TABLET | 2,016 | RCDRUGS371 |
| 372 | TAB GLIMEPRIDE 2MG | TABLET | 2,328 | RCDRUGS372 |
| 373 | TAB GLIMEPRIDE 2MG AND METFORMIN HCL 500MG SR | TABLET | 500 | RCDRUGS373 |
| 374 | INJ HUMAN INSULIN ACTRAPID 40IU / ml | INJ | 10 | RCDRUGS374 |
| 375 | INJ HUMAN INSULIN MIXTARD VIAL 30/70 40IU/ml | INJ | 16 | RCDRUGS375 |
| 376 | INJ HUMAN INSULIN NPH (ISOPHANE)(40iu/ml) 10ML VIAL | INJ | 10 | RCDRUGS376 |
| 377 | TAB METFORMIN 500MG | TABLET | 22,092 | RCDRUGS377 |
| 378 | TAB METFORMIN 500MG SR | TABLET | 5,000 | RCDRUGS378 |
| 270 | TAB SITAGLIPTIN PHOSPHATE MONOHYDRATE | | · | DCDDUCS270 |
| 379 | 50MG | TABLET | 300 | RCDRUGS379 |
| 380 | TAB SITAGLIPTIN PHOSPHATE MONOHYDRATE 100MG | TABLET | 100 | RCDRUGS380 |
| 381 | TAB TENEPRIDE 20MG | TABLET | 5,000 | RCDRUGS381 |
| 382 | TAB VILDAGLIPTIN 50MG | TABLET | 250 | RCDRUGS382 |
| 383 | TAB VOGLIBOSE 0.2MG | TABLET | 1,038 | RCDRUGS383 |
| 384 | TAB VOGLIBOSE 0.3MG | TABLET | 2,970 | RCDRUGS384 |
| | ANTI MICROBIALS AND CHEMOTHERA | PEUTIC DR | UGS | • |
| 385 | INJ ACYCLOVIR 500MG | INJ | 328 | RCDRUGS385 |
| 386 | INJ AMIKACIN 500MG/2ML – 2ML VIAL | INJ | 14,628 | RCDRUGS386 |
| 387 | CAP AMOXICILLIN 500MG | CAPS | 2,982 | RCDRUGS387 |
| 388 | INJ AMOXICILLIN + CLAVULANATE (1G + 200MG) VIAL | INJ | 144 | RCDRUGS388 |
| 389 | TAB AMOXICILLIN + CLAVULANATE 500MG+125MG | TABLET | 7,419 | RCDRUGS389 |
| 390 | TAB AMOXICILLIN 250 + CLAVULANATE 125MG | TABLET | 100 | RCDRUGS390 |
| 391 | SYRUP AMOXICILLIN + CLAVULANATE (3.3G/30ML) | SYRUP | 30 | RCDRUGS391 |
| 392 | INJ AMPICILLIN SULBACTAM 1.5GM | INJ | 1,000 | RCDRUGS392 |
| 393 | INJ AMPHOTERICIN B 50MG VIAL | INJ | 200 | RCDRUGS393 |
| 394 | INJ AMPHOTERICIN B 3-5MG LIPOSOMAL | INJ | 120 | RCDRUGS394 |
| 395 | TAB AZATHIOPRINE 50MG | TABLET | 97,581 | RCDRUGS395 |
| 396 | TAB AZITHROMYCIN 500MG | TABLET | 1,000 | RCDRUGS396 |
| 397 | INJ BENZYL PENCILLIN SODIUM IP 10LAKHS UNITS IM/IV VIAL | INJ | 650 | RCDRUGS397 |
| 398 | INJ CEFAPERAZONE WITH SULBACTUM 1GM | INJ | 12,202 | RCDRUGS398 |
| 399 | INJ CEFAZOLINE 1GM / VIAL | INJ | 13,302 | RCDRUGS399 |
| 400 | INJ CEFTAZIDIME 1GM/VIAL | INJ | 1,773 | RCDRUGS400 |
| 401 | INJ CEFTAZIDIME 2GM WITH AVIBACTUM 500MG | INJ | 500 | RCDRUGS401 |
| 402 | INJ CEFTRIAXONE 1GM/VIAL | INJ | 46,814 | RCDRUGS402 |
| 403 | INJ CEFIPIME 1GM/VIAL | INJ | 500 | RCDRUGS403 |
| 404 | INJ CHLORAMPHENICOL IGM USP | INJ | 700 | RCDRUGS404 |
| 405 | INJ CIPROFLOXACIN 200MG/100ML | INJ | 1,361 | RCDRUGS405 |
| 406 | TAB CIPROFLOXACIN HCL 500MG | TABLET | 6,876 | RCDRUGS406 |
| 407 | INJ COSPOFUNGIN 70MG | INJ | 30 | RCDRUGS407 |
| 408 | INJ COLISTIMETHATE SODIUM 1MIU | INJ | 6,959 | RCDRUGS408 |
| 409 | INJ CO-TRIMOXAZOLE 80/400MG 5ML AMP. | INJ | 42,000 | RCDRUGS409 |
| 410 | INJ CYCLOPHOSPHAMIDE 200MG | INJ | 10 | RCDRUGS410 |

| 413 TAB ETHAMBUTOL 400MG | | | | | |
|--|-----|---|---------------|--------|------------|
| 1413 TAB ETHAMBUTOL 400MG | 411 | INJ CYCLOPHOSPHAMIDE 500MG | INJ | 50 | RCDRUGS411 |
| TABLETT 1,000 RCDRUGS44 | | | | | |
| 415 | | | | | |
| 416 | | | | | |
| TAB FLUCONAZOLE 150MG | | | | | |
| 1418 TAB FLUCONAZOLE 200MG | | | | | |
| 11 | | | | | RCDRUGS417 |
| TAB FLUCONAZOLE 400MG | | | | | RCDRUGS418 |
| 421 TAB FLUCYTOSINE 500MG | | | | | RCDRUGS419 |
| A22 | | | | | RCDRUGS420 |
| 422 VIAL | 421 | | TABLET | 510 | RCDRUGS421 |
| 423 GLYCEROL) | 422 | VIAL | INJ | 8,636 | RCDRUGS422 |
| 134 | 423 | GLYCEROL) | LIQ | 827 | RCDRUGS423 |
| 426 TAB ISONIAZID I.P. 100MG | | VIAL | | | RCDRUGS424 |
| TAB ISONIAZID I.P. 300MG | | | | | RCDRUGS425 |
| 428 SYRUP ISONIAZID 100MG/5ML SYRUP 30 RCDRUGS42 429 TAB IVERMECTIN 12MG TABLET 500 RCDRUGS42 430 TAB LEVOFLOXACIN 500MG TABLET 200 RCDRUGS43 431 INJ LEVOFLOXACIN 500MG INJ 150 RCDRUGS43 432 TAB LINEZOLID 600 MG TABLET 100 RCDRUGS43 433 IV LINEZOLID 600MG IV 190 RCDRUGS43 434 LULICONAZOLE CREAM 1% W/W, 10 GRAM TUBE CREAM 60 RCDRUGS43 435 INJ MEROPENEM 500MG INJ 500 RCDRUGS43 436 INJ MEROPENEM 1GRAM INJ 800 RCDRUGS43 437 TAB METRONIDAZOLE 400mg BP TABLET 5,970 RCDRUGS43 438 INJ MERONIDAZOLE 5mg/ml IV 100ml PP INJ (IV) 18,075 RCDRUGS43 439 INJ MINOCYCLINE 100MG INJ (IV) 18,075 RCDRUGS44 441 TAB INTROFUNATOIN 100MG TABLET 1,225 RCDRUGS44 441 TAB ONT | | | | | RCDRUGS426 |
| 429 TAB IVERMECTIN 12MG | | | | | RCDRUGS427 |
| 430 | | | | | RCDRUGS428 |
| 431 INJ LEVOFLOXACIN 500MG | | | | | RCDRUGS429 |
| 432 TAB LINEZOLID 600 MG | | | | | RCDRUGS430 |
| 433 IV LINEZOLID 600MG | | | | | RCDRUGS431 |
| 434 LULICONAZOLE CREAM 1% W/W, 10 GRAM TUBE CREAM 60 RCDRUGS43 435 INJ MEROPENEM 500MG INJ 500 RCDRUGS43 436 INJ MEROPENEM 1GRAM INJ 800 RCDRUGS43 437 TAB METRONIDAZOLE 400mg BP TABLET 5,970 RCDRUGS43 438 INJ METRONIDAZOLE 5mg/ml IV 100ml PP CONTAINER INJ (IV) 18,075 RCDRUGS43 439 INJ MINOCYCLINE 100MG INJ 250 RCDRUGS43 440 TAB MYCOPHENOLATE MOFECIL (MMF) 500MG TABLET 1,225 RCDRUGS44 441 TAB NITROFURANTOIN 100MG TABLET 891 RCDRUGS44 442 TAB NORFLOXACIN 400MG TABLET 3,126 RCDRUGS44 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 2,224 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 448 CAP RIFAMPICIN 150MG TABLET 500 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS44 451 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG TABLET 72000 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADIAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 450 OINTMENT SILVER NITRAT | | | | | RCDRUGS432 |
| 435 INJ MEROPENEM 500MG | | | | | RCDRUGS433 |
| 436 INJ MEROPENEM 1GRAM | | , | | | RCDRUGS434 |
| 437 TAB METRONIDAZOLE 400mg BP TABLET 5,970 RCDRUGS43 438 INJ METRONIDAZOLE 5mg/ml IV 100ml PP CONTAINER INJ (IV) 18,075 RCDRUGS43 439 INJ MINOCYCLINE 100MG INJ 250 RCDRUGS43 440 TAB MYCOPHENOLATE MOFECIL (MMF) 500MG TABLET 1,225 RCDRUGS44 441 TAB NITROFURANTOIN 100MG TABLET 891 RCDRUGS44 442 TAB NORFLOXACIN 400MG TABLET 3,126 RCDRUGS44 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 449 CAP RIFAMPICIN 450MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 500MG INJ 10 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 10 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 450 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 45 | | | | | RCDRUGS435 |
| 183 | | | | | RCDRUGS436 |
| 10 | 437 | TAB METRONIDAZOLE 400mg BP | TABLET | 5,970 | RCDRUGS437 |
| 440 TAB MYCOPHENOLATE MOFECIL (MMF) 500MG TABLET 1,225 RCDRUGS44 441 TAB NITROFURANTOIN 100MG TABLET 891 RCDRUGS44 442 TAB NORFLOXACIN 400MG TABLET 3,126 RCDRUGS44 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG/100ML INJ 2,224 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 455 TAB | 438 | CONTAINER | · • | | RCDRUGS438 |
| 441 TAB NITROFURANTOIN 100MG TABLET 891 RCDRUGS44 442 TAB NORFLOXACIN 400MG TABLET 3,126 RCDRUGS44 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG/100ML INJ 2,224 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS45 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 455 TAB SULFADUAZINE 500MG< | | | | | RCDRUGS439 |
| 442 TAB NORFLOXACIN 400MG TABLET 3,126 RCDRUGS44 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG/100ML INJ 2,224 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADUAZ | 440 | | TABLET | 1,225 | RCDRUGS440 |
| 443 TAB OFLOXACIN 200MG TABLET 2,352 RCDRUGS44 444 INJ OFLOXACIN 200MG/100ML INJ 2,224 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 10,000 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS45 450 CAP RIFAMPICIN 600MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SI | 441 | | TABLET | 891 | RCDRUGS441 |
| 444 INJ OFLOXACIN 200MG/100ML INJ 2,224 RCDRUGS44 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W OINT 50 RCDRUGS45 457 O | 442 | TAB NORFLOXACIN 400MG | TABLET | 3,126 | RCDRUGS442 |
| 445 INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM INJ 5,509 RCDRUGS44 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 <t< td=""><td>443</td><td></td><td>TABLET</td><td></td><td>RCDRUGS443</td></t<> | 443 | | TABLET | | RCDRUGS443 |
| 446 TAB PYRAZINAMIDE 500MG TABLET 12,138 RCDRUGS44 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 <td>444</td> <td>INJ OFLOXACIN 200MG/100ML</td> <td></td> <td>2,224</td> <td>RCDRUGS444</td> | 444 | INJ OFLOXACIN 200MG/100ML | | 2,224 | RCDRUGS444 |
| 447 TAB PYRAZINAMIDE 750MG TABLET 500 RCDRUGS44 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS45 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | 445 | INJ PIPERACILLIN WITH TAZOBACTUM 4.5GM | INJ | 5,509 | RCDRUGS445 |
| 448 CAP RIFAMPICIN 150MG CAPS 8,532 RCDRUGS44 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | 12,138 | RCDRUGS446 |
| 449 CAP RIFAMPICIN 300MG CAPS 10,000 RCDRUGS44 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS447 |
| 450 CAP RIFAMPICIN 450MG CAPS 12,342 RCDRUGS45 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS448 |
| 451 CAP RIFAMPICIN 600MG CAPS 2,000 RCDRUGS45 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS449 |
| 452 INJ RITUXIMAB 100MG INJ 10 RCDRUGS45 453 INJ RITUXIMAB 500MG INJ 120 RCDRUGS45 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS450 |
| 453 INJ RITUXIMAB 500MG 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS 455 TAB SULFADUAZINE 500MG 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 CORUGS45 | | | | | RCDRUGS451 |
| 454 OINTMENT FRAMYCETIN SULPHATE P 1% W/W 30GMS 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS452 |
| 454 30GMS OINT 50 RCDRUGS45 455 TAB SULFADUAZINE 500MG TABLET 72000 RCDRUGS45 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | 453 | | INJ | 120 | RCDRUGS453 |
| 456 OINTMENT SILVER SULFADIAZINE 1% W/W 20GMS OINT 50 RCDRUGS45 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | 30GMS | | | RCDRUGS454 |
| 457 OINTMENT SILVER SULFADIAZINE 1% W/W 240GMS 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | | | | | RCDRUGS455 |
| 457 240GMS OINT 50 RCDRUGS45 458 OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS OINT 50 RCDRUGS45 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | 456 | | OINT | 50 | RCDRUGS456 |
| 459 OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS OINT 50 RCDRUGS45 | 457 | | OINT | 50 | RCDRUGS457 |
| | 458 | OINTMENT SILVER NITRATE I.P. 0.2% W/W 10GMS | OINT | 50 | RCDRUGS458 |
| 460 IN I STREPTOMYCIN SIII PHATE IP 1GM IN I 100 PCDDII CS46 | 459 | OINTMENT SILVER NITRATE I.P. 0.2% W/W 20GMS | OINT | 50 | RCDRUGS459 |
| TOU INDUSTRIES TO REPORT TO THE PROPERTY OF TH | 460 | INJ STREPTOMYCIN SULPHATE IP 1GM | INJ | 100 | RCDRUGS460 |

| 461 | INJ TIGECYCLINE 50MG LYOPHILISED POWDER | INJ | 175 | RCDRUGS461 |
|-----|---|--------|--------|------------|
| 462 | TAB TRIMETHOPRIM AND SULPHAMETHOXAZOLE | TABLET | 100 | RCDRUGS462 |
| 463 | INJ VANCOMYCIN 500MG | INJ | 11,347 | RCDRUGS463 |
| 464 | INJ VORICONAZOLE 200MG | INJ | 200 | RCDRUGS464 |
| 465 | TAB VORICONAZOLE 200MG | TABLET | 300 | RCDRUGS465 |
| | ANTI DOTES | | | |
| 466 | INJ MESNA 200MG | INJ | 76 | RCDRUGS466 |
| 467 | PROTAMINE SULPHATE 50MG/5ML VIAL | INJ | 661 | RCDRUGS467 |
| 468 | POLYVALANT ANTI SNAKE VENOM SERUM I.P. | INJ | 25 | RCDRUGS468 |
| | MINERALS & VITAMINS | 3 | ı | |
| 469 | TAB BIOTINE 10,000MCG | TABLET | 150 | RCDRUGS469 |
| 470 | TAB CALCIUM CARBONATE 500MG + VITAMIN D3 250MG | TABLET | 29,250 | RCDRUGS470 |
| 471 | INJ CALCIUM GLUCONATE 10% 10ML | INJ | 1,077 | RCDRUGS471 |
| 472 | SYRUP CALCIUM (CONTAINS CALCIUM, PHOSPHORUS, MAGNESIUM, ZINC & VITAMIN D3) | SYRUP | 1,200 | RCDRUGS472 |
| 473 | CAP CHOLEOCALCIFEROL 60K (VITAMIN D3) | CAPS | 173 | RCDRUGS473 |
| 474 | CAPSULES TAB FOLIC ACID 5MG | TABLET | 4,842 | RCDRUGS474 |
| 475 | CAP FERROUS ASCORBATE WITH FOLIC ACID | CAPS | 100 | RCDRUGS475 |
| 476 | CAP FERROUS FUMARATE 100MG, FOLIC ACID 1.5MG | CAPS | 100 | RCDRUGS476 |
| 477 | CAP FERROUS SULPHATE WITH B COMPLEX | CAPS | 150 | RCDRUGS477 |
| 478 | CAP FERROUS SULPHATE WITH FOLIC ACID | CAPS | 100 | RCDRUGS478 |
| 479 | HAEMATINIC (FERROUS FUMARATE WITH ELEMENTAL IRON EQUVALENT TO 100MG, FOLIC ACID, VIT. B6 AND B12) | CAPS | 20,919 | RCDRUGS479 |
| 480 | MECOBALAMINE AND MULTIVITAMINS COMBINATION (MECOBALAMINE 1500, PYRIDOXINE 20MG, FOLIC ACID 5MG) | TABLET | 500 | RCDRUGS480 |
| 481 | MENADIONE SODIUM 10MG/ ML | INJ | 366 | RCDRUGS481 |
| 482 | MULTIVITAMIN 10ML AMPS FOR INFUSION | IV | | RCDRUGS482 |
| 483 | INJ MAGNESIUM SULPHATE 50% 2ML AMP | INJ | 1,027 | RCDRUGS483 |
| 484 | TAB MECOBALAMINE PYRIDOXINE FOLIC ACID | TABLET | 500 | RCDRUGS484 |
| 485 | SYRUP POTASIUM CHLORIDE 1.5GM/15ML 200ML BOTTLE | SYRUP | 647 | RCDRUGS485 |
| 486 | INJ POTASIUM CHLORIDE 15% W/V, 1.5 GRAMS IN 10ML AMP | INJ | 8,813 | RCDRUGS486 |
| 487 | INJ PHYTONADIONE 1MG/0.5ML IM/IV 0.5ML AMP | INJ | 50 | RCDRUGS487 |
| 488 | INJ PHYTONADIONE 10MG/ML IM/IV 1ML AMP | INJ | 50 | RCDRUGS488 |
| 489 | TAB PYRIDOXINE HYDROCHLORIDE (VITAMIN B6) 40MG | TABLET | 53,589 | RCDRUGS489 |
| 490 | INJ SODIUM BICARBONATE 7.5% W/V 25ML AMP | INJ | 1,892 | RCDRUGS490 |
| 491 | INJ SODIUM BICARBONATE 8.4% 25ml | INJ | -, | RCDRUGS491 |
| 492 | SYRUP SODIUM FEREDETATE | SYRUP | 100 | RCDRUGS492 |
| 493 | TAB COMPOUND SODIUM BICORBONATE 500MG (SODAMINT) | TABLET | 51,000 | RCDRUGS493 |
| 494 | SODIUM FEREDETATE B.P. 231MG/5ML IN 150ML BOTTLE | SYRUP | 12 | RCDRUGS494 |
| 495 | TAB THIAMINE 100MG | TABLET | 500 | RCDRUGS495 |
| 496 | INJ THIAMINE 100MG/1ML 2ML | INJ | 5,000 | RCDRUGS496 |
| 497 | INJ THIAMINE HYDROCHLORIDE 500MG | INJ | 100 | RCDRUGS497 |
| | VITAMIN B1 100mg/ml (THIAMINE HYDROCHLORIDE IP 100mg, PYRIDOXINE IP 100mg | | | |
| 498 | CYANOCOBALAMIN IP 1000mcg, RIBOFLAVINE SODIUM PHOSPHATE IP 5mg, NICOTINAMIDE IP 100mg D-PANTHOLON IP 50mg) 3ml Amps | INJ | 15,114 | RCDRUGS498 |

| 499 | VITAMIN B1 100mg/ml (THIAMINE HYDROCHLORIDE IP 100mg, PYRIDOXINE IP 100mg CYANOCOBALAMIN IP 1000mcg, RIBOFLAVINE SODIUM PHOSPHATE IP 5mg, NICOTINAMIDE IP 100mg D-PANTHOLON IP 50mg) 10ml Amps | INJ | As and when required | RCDRUGS499 |
|-----|--|------------------|----------------------------|------------|
| 500 | VITAMIN B1 100mg/ml (THIAMINE HYDROCHLORIDE IP 100mg, PYRIDOXINE IP 100mg CYANOCOBALAMIN IP 1000mcg, RIBOFLAVINE SODIUM PHOSPHATE IP 5mg, NICOTINAMIDE IP 100mg D-PANTHOLON IP 50mg) 20ml Amps | INJ | As and when required | RCDRUGS500 |
| 501 | VITAMIN B1 100mg/ml (THIAMINE HYDROCHLORIDE IP 100mg, PYRIDOXINE IP 100mg CYANOCOBALAMIN IP 1000mcg, RIBOFLAVINE SODIUM PHOSPHATE IP 5mg, NICOTINAMIDE IP 100mg D-PANTHOLON IP 50mg) 50ml Amps | INJ | As and when required | RCDRUGS501 |
| 502 | CAP VITAMIN B1 10MG IP VIT.B6 3MG IP NICOTINAMIDE 100MG CALCIUM D-PANTETHENOL 50MG FOLIC ACID IP 1500MCG VIT.C 100MG | CAPS / TABLET | 12,58,19 1 | RCDRUGS502 |
| 503 | VITAMIN C IP 500MG CHEWABLE TABLET | TABLET | 3,750 | RCDRUGS503 |
| 504 | VITAMIN E 400MG | CAPS | 3,000 | RCDRUGS504 |
| 505 | VITAMIN E 600MG | CAPS | 200 | RCDRUGS505 |
| 506 | CAP ZINC ACETATE 50MG | CAPS | 1,500 | RCDRUGS506 |
| 507 | | | | |
| 507 | CAP ZINC SULPHATE 220MG | CAPS | 2,01,303 | RCDRUGS507 |
| 508 | PLASMA VOLUME EXPAND PLASMA VOLUME EXPANDER (TETRA STARCH) 6% SOLN 500ML | IV | 4,372 | RCDRUGS508 |
| | I.V. FLUIDS | | | |
| 509 | IV AMINO ACIDS SOLUTION 5% WITH SORBITOL (500ML) | IV | 1,000 | RCDRUGS509 |
| 510 | BALANCED ELECTROLYTE SOLUTION 500ML | IV | 7,161 | RCDRUGS510 |
| 511 | IV DEXTROSE 25% 100ML IN PP/GLASS CONTAINER | IV | 3,587 | RCDRUGS511 |
| 512 | IV DEXTROSE 5% WITH SODIUM CHLORIDE 0.9% 500ML IN PP CONTAINER | IV | 26,198 | RCDRUGS512 |
| 513 | IV DEXTROSE IP 5% 500ML IN PP CONTAINER | IV | 1,365 | RCDRUGS513 |
| 514 | IV ELECTROLYTE-P 500ML IN PP CONTAINER | IV | 413 | RCDRUGS514 |
| 515 | HUMAN ALBUMIN SOLUTION 20% 100ML | IV | 32 | RCDRUGS515 |
| 516 | IV MANNITOL 20% 100ML IN PP/GLASS CONTAINER | IV | 1,13,331 | RCDRUGS516 |
| 517 | IV RINGER'S LACTATE 500ML IN PP CONTAINER | IV | 40,484 | RCDRUGS517 |
| 317 | | IV | 40,404 | KCDKUG3511 |
| 518 | IV SODIUM CHLORIDE 0.9% 1,000ML IN PP CONTAINER ONLY | IV | 7,292 | RCDRUGS518 |
| 519 | IV SODIUM CHLORIDE 0.9% 100ML IN COLLAPSIBLE BAG | IV | 2,000 | RCDRUGS519 |
| 520 | IV SODIUM CHLORIDE 0.9% 100ML IN GLASS / PP CONTAINER | IV | 1,63,710 | RCDRUGS520 |
| 521 | IV SODIUM CHLORIDE 0.9% 500ML IN PP CONTAINER | IV | 1,68,247 | RCDRUGS521 |
| 522 | IV SODIUM CHLORIDE 3% 250ML IN PP/ GLASS BOTTLES | IV | 5,065 | RCDRUGS522 |
| 523 | IV SODIUM CHLORIDE 3% 100ML IN GLASS BOTTLES | IV | 5,065 | RCDRUGS523 |
| 524 | IV SODIUM CHLORIDE 3% 200ML IN GLASS BOTTLES | IV | 5,065 | RCDRUGS524 |
| 525 | IV SODIUM CHLORIDE 0.45% 500ML IN PP/ GLASS BOTTLE | IV | 2,893 | RCDRUGS525 |
| 526 | IV SODIUM CHLORIDE 0.45% WITH DEXTROSE 5% 500ML IN PP/GLASS CONTAINER | IV | 1,586 | RCDRUGS526 |

| 527 | IV SODIUM CHLORIDE 0.2% 500ML IN PP/ GLASS BOTTLE | IV | 1,000 | RCDRUGS527 |
|-----|--|--------------|--------|---------------|
| 528 | IV SODIUM CHLORIDE 0.2% WITH DEXTROSE 5% 500ML IN PP/GLASS CONTAINER | IV | 1,000 | RCDRUGS528 |
| 529 | SODIUM CHLORIDE 0.9% PREFILED SINGEL USE SYRINGE 5ML | IV | 12,000 | RCDRUGS529 |
| 530 | SODIUM CHLORIDE 0.9% PREFILED SINGEL USE SYRINGE 10ML | IV | 12,000 | RCDRUGS530 |
| 531 | STERILE WATER FOR INJECTION IP 5ML AMP PP CONTAINER ONLY | INJ | 39,336 | RCDRUGS531 |
| 532 | STERILE WATER FOR INJECTION IP 10ML AMP PP CONTAINER ONLY | INJ | 39,336 | RCDRUGS532 |
| | RE-HYDRATION POWDE | R | | |
| 533 | ANTI DEHYDRATION ELECTROLYTE POWDER 20.5GMS SACHET (WHO SPECIFICATIONS) | POWDER | 5,742 | RCDRUGS533 |
| | DRUGS ACTING ON RESPIRATOR | RY SYSTEM | | |
| 534 | CAP ACETYL CYSTEINE 600MG | CAPS | 1,050 | RCDRUGS534 |
| 535 | INJ ACETYL CYSTEINE 200MG/5ML | INJ | 6,733 | RCDRUGS535 |
| 536 | INJ AMINOPHYLLINE 250MG/10ML AMP | INJ | 161 | RCDRUGS536 |
| 537 | ASTHALINE NEBULISATION SOLUTION -5ML/15ML | 1145 | 101 | RCDRUGS537 |
| | | TABLET | 500 | |
| 538 | TAB BETAHISTINE 8MG | TABLET | 500 | RCDRUGS538 |
| 539 | TAB BETAHISTINE 16MG | TABLET | 500 | RCDRUGS539 |
| 540 | RESPULES BUDESONIDE 0.5MG/ 2ML RESPULES | RESPULE S | 756 | RCDRUGS540 |
| 541 | BUDESONIDE INHALER 200mcg | INHALER | | RCDRUGS541 |
| 542 | TAB CETRIZINE 10MG | TABLET | 31,254 | RCDRUGS542 |
| 543 | TAB CHLORPHENERAMINE MALLEATE 25 MG | TABLET | 100 | RCDRUGS543 |
| | SYRUP COUGH EXPECTORANT IN 120ML BOTTLE | | | |
| 544 | (PHENIRAMINE MALEATE OR DIPHENHYDRAMINE HCL & AMMONIUM CHLORIDE MENTHOL) | SYRUP | 4,865 | RCDRUGS544 |
| 545 | TAB DESLORATADINE 5MG | TABLET | 0 | RCDRUGS545 |
| 546 | TAB DOXYPHYLLINE 400MG | TABLET | 738 | RCDRUGS546 |
| 547 | TAB ETOPHYLLINE 77 MG THEOPHYLLINE 23MG | | | RCDRUGS547 |
| 547 | | TABLET | 1,884 | RCDRUGS541 |
| 548 | INJ ETOPHYLLINE BP 170MG WITH THEOPHYLLINE 50MG IM/IV 2ML | INJ | 3,995 | RCDRUGS548 |
| 549 | SYRUP HYDROXYZINE 10MG/5ML 100ML | SYRUP | 200 | RCDRUGS549 |
| 550 | IPRATROPIUM BROMIDE 500MG LEVOSALBUTAMOL 2.5MG/2.5ML RESPULES | RESPULE S | 1,221 | RCDRUGS550 |
| 551 | TAB METHYLCOBALAMINE 500MG | TABLET | 414 | RCDRUGS551 |
| 552 | INJ PHENIRAMINE MALEATE 22.75MG/ML 2ML | INJ | 2,000 | RCDRUGS552 |
| 553 | INJ PHENYLEPHRINE 10MG/ ML | INJ | 133 | RCDRUGS553 |
| 554 | INJ PHENYLEPHINE 50MG/ ML 10ML | INJ | 133 | RCDRUGS554 |
| 555 | TAB SALBUTAMOL 4MG | TABLET | 690 | RCDRUGS555 |
| 556 | SALBUTAMOL INHALER 200METERED DOSE 100MCG | INHELER | 500 | RCDRUGS556 |
| 557 | SALBUTAMOL RESPIRATOR SOLUTION 2.5MG/2.5ML | RESPULE S | 200 | RCDRUGS557 |
| 558 | SALBUTAMOL RESPIRATOR SOLUTION 5MG/15ML | SOLUTIO N | 200 | RCDRUGS558 |
| 559 | TERBUTALINE 0.5MG/ML | INJ | 500 | RCDRUGS559 |
| | REAGENTS | | | |
| 560 | ANTI SERA `A' 10ML VIAL (MONOCLONAL) | Reagent | 182 | RCDRUGS560 |
| 300 | ANTI SERA 'D' 10ML VIAL (IGG BLENDED WITH IGM) | Neagent | 104 | IVODIVO GOSOO |
| 561 | (MONOCLONAL) | Reagent | 156 | RCDRUGS561 |
| 562 | ANTI SERA `D' (IgG ONLY) 10ML VIAL (MONOCLONAL) | Reagent | 10 | RCDRUGS562 |
| 563 | ANTI SERA `D' (IgM ONLY) 10ML VIAL | Reagent | 5 | RCDRUGS563 |

| | (MONOCLONAL) | | | |
|------------|--|---------|--------|-------------|
| 564 | ANTI SERA `B' 10ML VIAL (MONOCLONAL) | Reagent | 150 | RCDRUGS564 |
| 565 | ANTI SERA `AB' 10ML VIAL (MONOCLONAL) | Reagent | 12 | RCDRUGS565 |
| 566 | A1 LECTIN 5ML VIAL | Reagent | 13 | RCDRUGS566 |
| 567 | ANTI HUMAN GLOBULIN (COOMBS SERA) 10ML | Reagent | 12 | RCDRUGS567 |
| 568 | H LECTIN (BOMBAY Oh PHENOTYPE) 5ML | Reagent | 132 | RCDRUGS568 |
| 569 | KITS RPR (SYPHILIS) 250 TESTS | Reagent | 10 | RCDRUGS569 |
| 570 | ANTI HCV ELISA KIT (IgG ANTI BODIES) 96 TEST | KĬT | 45 | RCDRUGS570 |
| 571 | ANTI HIV ELISA KIT 96 TEST | KIT | 45 | RCDRUGS571 |
| 572 | HBs Ag ELISA TEST KIT 96 TESTS | KIT | 45 | RCDRUGS572 |
| 573 | RAPID HCV TEST 50 TEST PACK | KIT | 5 | RCDRUGS573 |
| 574 | RAPID HIV TEST 50 TEST PACK | KIT | 5 | RCDRUGS574 |
| 575 | RAPID HBs Ag TEST 50 TEST PACK | KIT | 10 | RCDRUGS575 |
| 576 | RAPID CARD TEST FOR OCCULT BLOOD IN | KIT | 10 | RCDRUGS576 |
| 370 | STOOLS | KH | 10 | KODKOG5370 |
| 577 | REAGENT STRIP KITS FOR RAPID DETECTION OF OCCULT BLOOD IN FAECES | KIT | 100 | RCDRUGS577 |
| | MALARIA CARD (RAPID TEST) FOR DETECTING | | | |
| | FALCIPARUM MALARIA AND NON-FALCIPARUM | | | |
| 578 | MALARIA (CARD SHOULD HAVE CLEAR | KIT | 300 | RCDRUGS578 |
| | INDICATORS 'C' FOR CONTROL BAND, 'PAN' FOR | | | |
| | NON-FALCIPARUM MALARIA AND 'PF' FOR FACLIPARUM MALARIA) | | | |
| | HERPES SIMPLEX VIRUS POLYMERASE CHAIN | | | |
| 579 | REACTION KIT (HSV PCR KIT) | KIT | | RCDRUGS579 |
| | URINE ANALYSIS REAGENT FOR KETONE BODIES | | | |
| 580 | (100 STRIPS PER BOTTLE) | KIT | | RCDRUGS580 |
| 581 | URINE ANALYSIS REAGENT FOR MUTIPLE | KIT | 40 | RCDRUGS581 |
| 501 | PARAMETERS (100 STRIPS PER BOTTLE) | KII | 40 | KCDKUG5561 |
| 582 | PREGNANCY TEST KIT | KIT | 10 | RCDRUGS582 |
| | ANTI SEPTIC AND DISINFEC | TANTS | | |
| 583 | **ALCOHOL RUB-IN-HAND DISINFECTANT 500ML (70% ISOPROPYL ALCOHOL, 2-PROPANOL) | LIQ | 12,448 | RCDRUGS583 |
| 504 | **LIQ CHLORHEXIDINE GLUCONATE 2 TO 2.5% | 1.10 | 400 | DODDIIO0504 |
| 584 | (W/V) IN ISOPROPYL ALCOHOL 70% (V/V) 500ML | LIQ | 100 | RCDRUGS584 |
| E0.E | **LIQ CHLORHEXIDINE GLUCONATE SOLUTION BP | 1.10 | 42.045 | DCDDUCCEOE |
| 585 | 20% V/V 4%W/V 500ML BOTTLE/JAR | LIQ | 13,915 | RCDRUGS585 |
| | LIQ CHEMICALLY BONDED FORMALDEHYDE WITH | | | |
| 586 | GLUTRALDEHYDE FOR QUICK SURFACE | LIQ | 1,013 | RCDRUGS586 |
| | ENVIRONMENT DISINFECTANT 5 LITRES CAN | | | |
| | LIQ. CHLORHEXIDINE HCL BP 7.5% V/V WITH | | | |
| 587 | CETRIMIDE 15% w/v + 70% ISOPROPYL ALCOHOL - | LIQ | 60 | RCDRUGS587 |
| | 1LITRE BOTTLE | | | ļ |
| 500 | LIQ EIROX VAPORISED HYDROGEN PEROXIDE | | 4 000 | DODDUGGESS |
| 588 | BASED FOGGING DISINFECTANT [WATERLESS | LIQ | 1,000 | RCDRUGS588 |
| | FUMIGATION CHEMICAL] 5 LIR CAN | | | |
| 589 | LIQ GLUTARALDEHYDE 2% SOLUTION 5 LITRES CAN | LIQ | 1,206 | RCDRUGS589 |
| | | | | |
| 590 | LIQ HYDROGEN PEROXIDE SOLUTION 450ML BOTTLE | LIQ | 3,009 | RCDRUGS590 |
| | LIQ INSTA-ACT 250ML- ETHANOL,2-PROPANOL & | | | |
| 591 | 1-PROPANOL LIQUID-SURFACE AND EQUIPMENT | LIQ | 1,410 | RCDRUGS591 |
| | DISINFECTANT (ALDEHYDE FREE)- | | 05 555 | D0DD1100-0- |
| 592 | LIQ SODIUM HYPOCHLORITE SOLUTION 5% 5LTR | LIQ | 85,722 | RCDRUGS592 |
| F00 | ANTI SEPTIC GEL CONTAINING ALUMINUM OXIDE, | OINT | 40 | DODDUOGEGG |
| 593 | 1,2-PROPSNRFIOL, SODIUM POLYACRYLATE, | OINT | 40 | RCDRUGS593 |
| | METHYLPARADEN, PROPYPARADEN | | | |

| | ANTI SERTIC I OTION CONTAINING OCTENIDINE | <u> </u> | I | 1 | | |
|----------|--|----------|--------|------------|--|--|
| 594 | ANTI SEPTIC LOTION CONTAINING OCTENIDINE HCL 150ML BOTTLE | LIQ | 1,800 | RCDRUGS594 | | |
| 595 | INSTRUMENT DISINFECTANT CONTAINING 7.7G DIDECYLDIMETHYLAMMONIUM CHLORIDE, 0.4G OF POLYHEXAMETHYLENE BUGUANIDE 2LITER BOTTLE | LIQ | 360 | RCDRUGS595 | | |
| 596 | OINT MUPIROCIN 2% | OINT | 3,630 | RCDRUGS596 | | |
| 597 | OINT. POVIDONE IODINE I.P. 5% w/w - 125GM TUBE | OINT | 631 | RCDRUGS597 | | |
| 598 | LIQ POVIDONE IODINE 5% 500ML BOTTLE | LIQ | 3,227 | RCDRUGS598 | | |
| 599 | ** LIQ. POVIDONE IODINE 7.5% w/v SCRUB 500ML BOTTLE | LIQ | 1,031 | RCDRUGS599 | | |
| 600 | POLYMERIC BIAGUANIDE HYDROCHLORIDE 10% (ALKYL DIMETHYL BENZYL AMMONIUM CHLORIDE & DIDECYL DIMETHYL AMMONIUM CHLORIDE) 10% WITH ADDED PHMD (SANIHIEGENE) 1LITRE | LIQ | 500 | RCDRUGS600 | | |
| 601 | POLYMERIC BIAGUANIDE HYDROCHLORIDE 10% (ALKYL DIMETHYL BENZYL AMMONIUM CHLORIDE & DIDECYL DIMETHYL AMMONIUM CHLORIDE) 10% WITH ADDED PHMD (SANIHIEGENE) 5LITRE | LIQ | 500 | RCDRUGS601 | | |
| 602 | 2 PROPANOL 40GM, 1-PROPANOL 22GM (EQUIVALENT TO 69% ALCOHOL - CONTAINE 100GMS) (SANIOCID RF) - 1,000ML | LIQ | 500 | RCDRUGS602 | | |
| 603 | 2 PROPANOL 40GM, 1-PROPANOL 22GM (EQUIVALENT TO 69% ALCOHOL - CONTAINE 100GMS) (SANIOCID RF) - 250ML | LIQ | 500 | RCDRUGS603 | | |
| 604 | TAB SODIUM DICHLOROISOCYANURATE (NaDCC) 50TABLET/BOX | TABLET | 1,200 | RCDRUGS604 | | |
| 605 | TAB PARAFORMALDEHYDE 1GM | TABLET | 28,980 | RCDRUGS605 | | |
| 623 | ABSOLUTE ALCOHOL 5LTRS, 50LIRS, 100LTRS. CANS | LIQ | 5,640 | RCDRUGS623 | | |
| 624 | RECTIFIED SPIRIT 5LTRS, 50LIRS, 100LTRS. CANS | LIQ | 12,000 | RCDRUGS624 | | |
| VACCINES | | | | | | |
| 606 | INJ HEPATITIS B VACCINE (MULTIDOSE) 10ML VIAL | INJ | 124 | RCDRUGS606 | | |
| 607 | HUMAN RABIES IMMUNOGLOBULIN 150IU/ML 2ML VIAL | INJ | | RCDRUGS607 | | |
| 608 | INJ RABIES VACCINES CELL CULTURE 2.5 IU | INJ | 307 | RCDRUGS608 | | |
| 609 | INJ TETANUS TOXOID VACCINE (ADSORBED) IP 0.5ML AMPS | INJ | 1,929 | RCDRUGS609 | | |
| | Miscellaneous | | | | | |
| 610 | CHLORHEXIDINE MOUTHWASH | | 54 | RCDRUGS610 | | |
| | SURIGAL AND MISCELLAN | EOUS | | | | |
| 611 | SINGLE BLOOD BAG SYSTEM WITH 49ML CPDA/CPDA-1 SOLUTION 350ML CAPACITY | BAG | 60 | RCDRUGS611 | | |
| 612 | DOUBLE BLOOD BAG SYSTEM WITH 63ML CPDA/CPDA-1 SOLUTION 450ML CAPACITY | BAG | 859 | RCDRUGS612 | | |
| 613 | DOUBLE BLOOD BAG SYSTEM WITH 49ML CPDA/CPDA-1 SOLUTION 350ML CAPACITY | BAG | 1,426 | RCDRUGS613 | | |
| 614 | TRIPLE BLOOD BAG SYSTEM 63ML CPD/CPDA/CPDA1 SOLUTION WITH 450ML CAPACITY BAG FOR PLATELETS FOR 5 DAYS STORAGE | BAG | 0 | RCDRUGS614 | | |
| 615 | QUADRUPLE BLOOD BAG (TOP AND BOTTOM) SYSTEM WITH 49ML CPDA/CPDA-1 SOLUTION 350ML CAPACITY | BAG | 2,591 | RCDRUGS615 | | |
| | | | | | | |
| 616 | QUADRUPLE BLOOD BAG (TOP AND BOTTOM) SYSTEM WITH 63ML CPDA/CPDA-1 SOLUTION | BAG | 500 | RCDRUGS616 | | |

| | 450ML CAPACITY | | | |
|-----|--|-----|-------|------------|
| 617 | TRANSFER BLOOD BAGS OF 100 ML CAPACITY | BAG | 120 | RCDRUGS617 |
| 618 | TRANSFER BLOOD BAGS OF 300 ML CAPACITY | BAG | 600 | RCDRUGS618 |
| | TRIPLE BLOOD BAG OF 350ML CAPACITY WITH | | | |
| 619 | 49ML OF CPD/CPDA AND SAGM SOLUTION OFR | BAG | 2,000 | RCDRUGS619 |
| 620 | PLATELETS 5 DAYS STORAGE | | | |
| | TRIPLE BLOOD BAG SYSTEM 63ML | | | |
| | CPD/CPDA/CPDA1 SOLUTION 450ML CAPACITY | BAG | 2,500 | RCDRUGS620 |
| | AND SAGM SOLUTION OFFERING 5 DAYS | | | |
| | STORAGE OF PLATELETS | | | |
| 621 | QUADRUPLE BLOOD BAG (TOP AND TOP) OF | | | |
| | 350ML CAPACITY WITH 49ML OF CPD/CPDA AND | BAG | 500 | RCDRUGS621 |
| | SAGM SOLUTION | | | |
| 622 | QUADRUPLE BLOOD BAG (TOP AND TOP) OF | | | |
| | 450ML CAPACITY WITH 63ML OF CPD/CPDA AND | BAG | 500 | RCDRUGS622 |
| | SAGM SOLUTION | | | |

 $^{^{***}}$ SI. No. 299,300,301 SAID DRUGS MANUFACTURERS HAS TO SUPPLY VAPORISERS ON FINALIZATION

^{**} SI. No. 583,584,585,599 SAID DRUGS MANUFACTURERS HAS TO SUPPLY DISPENSING STANDS (BOTH BED SIDE AND WALLMOUNT) ON FINALIZATION